{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T10:46:26Z","timestamp":1782297986745,"version":"3.54.5"},"reference-count":326,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04474-7","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T09:50:25Z","timestamp":1782294625000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in targeted and cellular therapies for relapsed\/refractory mantle cell lymphoma: immunotherapeutic strategies and challenges"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8312-4938","authenticated-orcid":false,"given":"Azhagu Madhavan","family":"Sivalingam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"4474_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2026.04.006","author":"AC Meireles","year":"2026","unstructured":"Meireles AC, Resende PM, Korin L, Schmidt JD, Perini GF. Accessing BTK inhibitors and other novel therapies for mantle cell lymphoma: are we all invited to the party? Clin Lymphoma Myeloma Leuk. 2026. https:\/\/doi.org\/10.1016\/j.clml.2026.04.006.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4474_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102318","volume":"6","author":"H Wan","year":"2025","unstructured":"Wan H, Ren W, Yang M, et al. Tumor evolution and immune microenvironment dynamics in primary and relapsed mantle cell lymphoma. Cell Rep Med. 2025;6:102318. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102318.","journal-title":"Cell Rep Med"},{"key":"4474_CR3","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025018701","author":"Y Yan","year":"2026","unstructured":"Yan Y, Chen W, Ge X, et al. Proteogenomic features define subtypes of mantle cell lymphoma. Blood Adv. 2026. https:\/\/doi.org\/10.1182\/bloodadvances.2025018701.","journal-title":"Blood Adv"},{"key":"4474_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1182\/bloodadvances.2025017234","volume":"10","author":"M Aymard","year":"2026","unstructured":"Aymard M, Cheminant M, Houot R, et al. Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group. Blood Adv. 2026;10:75\u201382. https:\/\/doi.org\/10.1182\/bloodadvances.2025017234.","journal-title":"Blood Adv"},{"key":"4474_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood.2023021306","volume":"143","author":"A Minson","year":"2024","unstructured":"Minson A, Hamad N, Cheah CY, et al. CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study. Blood. 2024;143:673\u201384. https:\/\/doi.org\/10.1182\/blood.2023021306.","journal-title":"Blood"},{"key":"4474_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2024.100484","volume":"22","author":"R Chiriac","year":"2024","unstructured":"Chiriac R, Donzel M, Baseggio L. A rapid progression from classical mantle cell lymphoma to a blastoid variant. Leuk Res Rep. 2024;22:100484. https:\/\/doi.org\/10.1016\/j.lrr.2024.100484.","journal-title":"Leuk Res Rep"},{"key":"4474_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.hoc.2026.01.001","volume":"40","author":"AD Dreyfuss","year":"2026","unstructured":"Dreyfuss AD, Yahalom J. The modern role of radiation therapy in classic hodgkin lymphoma. Hematol Oncol Clin North Am. 2026;40:257\u201374. https:\/\/doi.org\/10.1016\/j.hoc.2026.01.001.","journal-title":"Hematol Oncol Clin North Am"},{"key":"4474_CR8","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2026.02.003","author":"R Lakhotia","year":"2026","unstructured":"Lakhotia R, Roschewski M. Minimal residual disease guided treatment approaches in non-Hodgkin lymphoma\u2014Where we are and where we\u2019re headed. Semin Hematol. 2026. https:\/\/doi.org\/10.1053\/j.seminhematol.2026.02.003.","journal-title":"Semin Hematol"},{"key":"4474_CR9","doi-asserted-by":"publisher","first-page":"S851","DOI":"10.1016\/S2152-2650(25)02473-5","volume":"25","author":"A Lal","year":"2025","unstructured":"Lal A, Yadav S, Mineishi S. MCL-643: Unmasking Hodgkin-like features in mantle cell lymphoma after CAR-T therapy: a case of composite lymphoma. Clin Lymphoma Myeloma Leuk. 2025;25:S851\u20132. https:\/\/doi.org\/10.1016\/S2152-2650(25)02473-5.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4474_CR10","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1182\/bloodadvances.2023011763","volume":"8","author":"C L\u00f3pez","year":"2024","unstructured":"L\u00f3pez C, Silkenstedt E, Dreyling M, Be\u00e0 S. Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma. Blood Adv. 2024;8:3652\u201364. https:\/\/doi.org\/10.1182\/bloodadvances.2023011763.","journal-title":"Blood Adv"},{"key":"4474_CR11","doi-asserted-by":"publisher","first-page":"S518","DOI":"10.1016\/S2152-2650(24)01606-9","volume":"24","author":"R Prasad Dutta","year":"2024","unstructured":"Prasad Dutta R, Huan Lee H-H, Leshchenko VV, et al. MCL-762 SOX11 inhibits BCR signaling through the PAX5\/CD19 axis for therapeutic targeting in BTK and BCL2 inhibitor resistant mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2024;24:S518\u20139. https:\/\/doi.org\/10.1016\/S2152-2650(24)01606-9.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4474_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2026.102794","volume":"69","author":"L Dong","year":"2026","unstructured":"Dong L, Zhang Y, Chen F, et al. Eprenetapopt in combination with Palbociclib exerts synthetic lethality in mantle cell lymphoma. Transl Oncol. 2026;69:102794. https:\/\/doi.org\/10.1016\/j.tranon.2026.102794.","journal-title":"Transl Oncol"},{"key":"4474_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104085","volume":"190","author":"NR Raghani","year":"2023","unstructured":"Raghani NR, Shah DD, Shah TS, Chorawala MR, Patel RB. Combating relapsed and refractory mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects. Crit Rev Oncol Hematol. 2023;190:104085. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104085.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4474_CR14","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1182\/bloodadvances.2025017760","volume":"10","author":"J Ruan","year":"2026","unstructured":"Ruan J, Bond DA, Shah B, et al. MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma. Blood Adv. 2026;10:1381\u201394. https:\/\/doi.org\/10.1182\/bloodadvances.2025017760.","journal-title":"Blood Adv"},{"key":"4474_CR15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.trecan.2025.12.007","volume":"12","author":"J Tao","year":"2026","unstructured":"Tao J, Qiu K, Williams ME. Targeting persister cells: proactively overcoming therapy resistance in aggressive B cell lymphomas. Trends Cancer. 2026;12:370\u201381. https:\/\/doi.org\/10.1016\/j.trecan.2025.12.007.","journal-title":"Trends Cancer"},{"key":"4474_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefro.2026.501512","author":"C Veiga","year":"2026","unstructured":"Veiga C, Dam\u00e1sio I, Milheiro J, et al. Reversible podocytopathy in a patient with blastoid-variant mantle cell lymphoma: a case of paraneoplastic FSGS and a literature review. Nefrologia. 2026. https:\/\/doi.org\/10.1016\/j.nefro.2026.501512.","journal-title":"Nefrologia"},{"key":"4474_CR17","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1182\/bloodadvances.2025016688","volume":"10","author":"R Xu","year":"2026","unstructured":"Xu R, Wu G, Rice S, et al. Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy. Blood Adv. 2026;10:3845\u201355. https:\/\/doi.org\/10.1182\/bloodadvances.2025016688.","journal-title":"Blood Adv"},{"key":"4474_CR18","doi-asserted-by":"publisher","first-page":"e777","DOI":"10.1016\/S2352-3026(25)00252-2","volume":"12","author":"C Visco","year":"2025","unstructured":"Visco C, Tabanelli V, Sacchi MV, et al. Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study. Lancet Haematol. 2025;12:e777\u201388. https:\/\/doi.org\/10.1016\/S2352-3026(25)00252-2.","journal-title":"Lancet Haematol"},{"key":"4474_CR19","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1182\/bloodadvances.2025018667","volume":"10","author":"F Stedema","year":"2026","unstructured":"Stedema F, Brink M, Huisman F, et al. Impact of rituximab maintenance on survival in patients with mantle cell lymphoma: a population-based cohort study. Blood Adv. 2026;10:2916\u201324. https:\/\/doi.org\/10.1182\/bloodadvances.2025018667.","journal-title":"Blood Adv"},{"key":"4474_CR20","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1182\/blood.2024026919","volume":"146","author":"W Wang","year":"2025","unstructured":"Wang W, Cai Q, Liu Y, et al. TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma. Blood. 2025;146:2544\u201360. https:\/\/doi.org\/10.1182\/blood.2024026919.","journal-title":"Blood"},{"key":"4474_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108870","volume":"34","author":"X Zhao","year":"2021","unstructured":"Zhao X, Wang MY, Jiang H, et al. Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma. Cell Rep. 2021;34:108870. https:\/\/doi.org\/10.1016\/j.celrep.2021.108870.","journal-title":"Cell Rep"},{"key":"4474_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.radonc.2022.08.007","volume":"175","author":"HS Ababneh","year":"2022","unstructured":"Ababneh HS, Abramson JS, Johnson PC, Patel CG. Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy. Radiother Oncol. 2022;175:65\u201372. https:\/\/doi.org\/10.1016\/j.radonc.2022.08.007.","journal-title":"Radiother Oncol"},{"key":"4474_CR23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.hoc.2019.03.002","volume":"33","author":"B Diamond","year":"2019","unstructured":"Diamond B, Kumar A. mantle cell lymphoma: current and emerging treatment strategies and unanswered questions. Hematol Oncol Clin North Am. 2019;33:613\u201326. https:\/\/doi.org\/10.1016\/j.hoc.2019.03.002.","journal-title":"Hematol Oncol Clin North Am"},{"key":"4474_CR24","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jtct.2022.07.015","volume":"28","author":"SR Goldsmith","year":"2022","unstructured":"Goldsmith SR, Ghobadi A, Dipersio JF, Hill B, Shadman M, Jain T. Chimeric antigen receptor T Cell therapy versus hematopoietic stem cell transplantation: an evolving perspective. Trans Cell Thera. 2022;28:727\u201336. https:\/\/doi.org\/10.1016\/j.jtct.2022.07.015.","journal-title":"Trans Cell Thera"},{"key":"4474_CR25","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2024-193091","volume":"144","author":"ZD Epstein-Peterson","year":"2024","unstructured":"Epstein-Peterson ZD, Ryan CE, Devlin SM, et al. Tumor determinants of response to CAR-T therapy in relapsed or refractory mantle cell lymphoma. Blood. 2024;144:4393. https:\/\/doi.org\/10.1182\/blood-2024-193091.","journal-title":"Blood"},{"key":"4474_CR26","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jtct.2021.08.016","volume":"27","author":"HE Heslop","year":"2021","unstructured":"Heslop HE, Stadtmauer EA, Levine JE, et al. Blood and marrow transplant clinical trials network state of the science symposium 2021: looking forward as the network celebrates its 20th year. Transp Cell Thera. 2021;27:885\u2013907. https:\/\/doi.org\/10.1016\/j.jtct.2021.08.016.","journal-title":"Transp Cell Thera"},{"key":"4474_CR27","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.bbmt.2011.09.009","volume":"18","author":"E Jantunen","year":"2012","unstructured":"Jantunen E, Sureda A. the evolving role of stem cell transplants in lymphomas. Biol Blood Marrow Transp. 2012;18:660\u201373. https:\/\/doi.org\/10.1016\/j.bbmt.2011.09.009.","journal-title":"Biol Blood Marrow Transp"},{"key":"4474_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2017.05.008","volume":"58","author":"P Martin","year":"2017","unstructured":"Martin P, Ghione P, Dreyling M. Mantle cell lymphoma\u2014Current standards of care and future directions. Cancer Treat Rev. 2017;58:51\u201360. https:\/\/doi.org\/10.1016\/j.ctrv.2017.05.008.","journal-title":"Cancer Treat Rev"},{"key":"4474_CR29","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jtct.2021.03.001","volume":"27","author":"PN Munshi","year":"2021","unstructured":"Munshi PN, Hamadani M, Kumar A, et al. American society of transplantation and cellular therapy, center of international blood and marrow transplant research, and european society for blood and marrow transplantation clinical practice recommendations for transplantation and cellular therapies in mantle cell lymphoma. Transp Cell Thera. 2021;27:720\u20138. https:\/\/doi.org\/10.1016\/j.jtct.2021.03.001.","journal-title":"Transp Cell Thera"},{"key":"4474_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2025.156036","volume":"271","author":"S Patil","year":"2025","unstructured":"Patil S, Rajput S, Patil S, Mhaiskar A. B-cell lymphoma: advances in pathogenesis, diagnosis, and targeted therapies. Pathology\u2014Res Prac. 2025;271:156036. https:\/\/doi.org\/10.1016\/j.prp.2025.156036.","journal-title":"Pathology\u2014Res Prac"},{"key":"4474_CR31","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1182\/blood.2023022352","volume":"145","author":"CE Ryan","year":"2025","unstructured":"Ryan CE, Armand P, LaCasce AS. Frontline management of mantle cell lymphoma. Blood. 2025;145:663\u201372. https:\/\/doi.org\/10.1182\/blood.2023022352.","journal-title":"Blood"},{"key":"4474_CR32","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.bnd.2025.06.003","volume":"1","author":"A Abbas","year":"2025","unstructured":"Abbas A, Sabet H, Abouelmagd ME, et al. Safety and efficacy of Bruton\u2019s tyrosine kinase inhibitors in multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials. Brain Netw Disord. 2025;1:230\u20138. https:\/\/doi.org\/10.1016\/j.bnd.2025.06.003.","journal-title":"Brain Netw Disord"},{"key":"4474_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2019.100201","volume":"10","author":"Y Ariza","year":"2019","unstructured":"Ariza Y, Murata M, Ueda Y, Yoshizawa T. Bruton\u2019s tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption. Bone Rep. 2019;10:100201. https:\/\/doi.org\/10.1016\/j.bonr.2019.100201.","journal-title":"Bone Rep"},{"key":"4474_CR34","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jacc.2025.10.018","volume":"87","author":"S Ganatra","year":"2026","unstructured":"Ganatra S, Barac A, Armenian S, et al. Diagnosis and management of cardiovascular adverse effects of targeted oncology therapies: bruton\u2019s tyrosine kinase, immune checkpoint, and vascular endothelial growth factor inhibitors: 2025 acc concise clinical guidance: a report of the american college of cardiology solution set oversight committee. JACC. 2026;87:654\u201382. https:\/\/doi.org\/10.1016\/j.jacc.2025.10.018.","journal-title":"JACC"},{"key":"4474_CR35","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.omtn.2021.12.014","volume":"27","author":"DH Gray","year":"2022","unstructured":"Gray DH, Santos J, Keir AG, et al. A comparison of DNA repair pathways to achieve a site-specific gene modification of the Bruton\u2019s tyrosine kinase gene. Mol Thera Nucleic Acids. 2022;27:505\u201316. https:\/\/doi.org\/10.1016\/j.omtn.2021.12.014.","journal-title":"Mol Thera Nucleic Acids"},{"key":"4474_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2026.05.039","author":"A Mian","year":"2026","unstructured":"Mian A, Litvin R, Dima D, et al. Neighborhood socioeconomic disadvantage and distance from treatment center do not impact survival outcomes of patients with non-Hodgkin lymphoma and multiple myeloma treated with CAR T-cell therapies. Transp Cell Ther. 2026. https:\/\/doi.org\/10.1016\/j.jtct.2026.05.039.","journal-title":"Transp Cell Ther"},{"key":"4474_CR37","doi-asserted-by":"publisher","first-page":"14129","DOI":"10.1021\/acs.jmedchem.1c01279","volume":"64","author":"W Kawahata","year":"2021","unstructured":"Kawahata W, Asami T, Kiyoi T, et al. Discovery of AS-1763: a potent, selective, noncovalent, and orally available inhibitor of Bruton\u2019s tyrosine kinase. J Med Chem. 2021;64:14129\u201341. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01279.","journal-title":"J Med Chem"},{"key":"4474_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105267","volume":"222","author":"D Kegyes","year":"2026","unstructured":"Kegyes D, Muresan X, Bancos A, et al. Integrating venetoclax-based targeted and\/or immune therapies for chronic lymphocytic leukemia. Crit Rev Oncol Hematol. 2026;222:105267. https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105267.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4474_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.crstbi.2026.100186","volume":"11","author":"A Khan","year":"2026","unstructured":"Khan A, Sawali MA, Shkoor M, et al. Computational hybrid framework integrating clinical-mutation profiling and physics-based simulations to predict structural tolerance of Bruton tyrosine kinase (BTK) and sustained ARQ 531 binding. Current Res Struct Biol. 2026;11:100186. https:\/\/doi.org\/10.1016\/j.crstbi.2026.100186.","journal-title":"Current Res Struct Biol"},{"key":"4474_CR40","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.jaci.2024.10.035","volume":"155","author":"VNC Leal","year":"2025","unstructured":"Leal VNC, Bork F, Mateo Tortola M, et al. Bruton\u2019s tyrosine kinase (BTK) and matrix metalloproteinase-9 (MMP-9) regulate NLRP3 inflammasome-dependent cytokine and neutrophil extracellular trap responses in primary neutrophils. J Allergy Clini Immunol. 2025;155:569\u201382. https:\/\/doi.org\/10.1016\/j.jaci.2024.10.035.","journal-title":"J Allergy Clini Immunol"},{"key":"4474_CR41","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.hoc.2020.06.008","volume":"34","author":"R McCulloch","year":"2020","unstructured":"McCulloch R, Eyre TA, Rule S. What causes bruton tyrosine kinase inhibitor resistance in mantle cell lymphoma and how should we treat such patients? Hematol Oncol Clin North Am. 2020;34:923\u201339. https:\/\/doi.org\/10.1016\/j.hoc.2020.06.008.","journal-title":"Hematol Oncol Clin North Am"},{"key":"4474_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2026.104606","volume":"117","author":"FJ Navarro-Trivi\u00f1o","year":"2026","unstructured":"Navarro-Trivi\u00f1o FJ, Ruiz-Villaverde R. Bruton\u2019s tyrosine kinase (BTK) inhibitors: a new therapeutic frontier in dermatology. Actas Dermosifiliogr. 2026;117:104606. https:\/\/doi.org\/10.1016\/j.ad.2026.104606.","journal-title":"Actas Dermosifiliogr"},{"key":"4474_CR43","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1021\/acs.jmedchem.1c01170","volume":"65","author":"TD Owens","year":"2022","unstructured":"Owens TD, Brameld KA, Verner EJ, et al. Discovery of reversible covalent bruton\u2019s tyrosine kinase inhibitors PRN473 and PRN1008 (Rilzabrutinib). J Med Chem. 2022;65:5300\u201316. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01170.","journal-title":"J Med Chem"},{"key":"4474_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmgm.2024.108762","volume":"130","author":"E Sambur","year":"2024","unstructured":"Sambur E, Oktay L, Durda\u011f\u0131 S. Covalent docking-driven virtual screening of extensive small-molecule libraries against Bruton tyrosine kinase for the identification of highly selective and potent novel therapeutic candidates. J Mol Graph Model. 2024;130:108762. https:\/\/doi.org\/10.1016\/j.jmgm.2024.108762.","journal-title":"J Mol Graph Model"},{"key":"4474_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2026.106199","author":"I Sarami","year":"2026","unstructured":"Sarami I, Medeiros LJ. CAR-T cell therapy and its complications: role of the pathologist in diagnosis. Human Pathol. 2026. https:\/\/doi.org\/10.1016\/j.humpath.2026.106199.","journal-title":"Human Pathol"},{"key":"4474_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155607","volume":"263","author":"V Sankarapandian","year":"2024","unstructured":"Sankarapandian V, Rajendran RL, Miruka CO, et al. A review on tyrosine kinase inhibitors for targeted breast cancer therapy. Pathol\u2014Res Pract. 2024;263:155607. https:\/\/doi.org\/10.1016\/j.prp.2024.155607.","journal-title":"Pathol\u2014Res Pract"},{"key":"4474_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2026.103346","volume":"26","author":"B Xu","year":"2026","unstructured":"Xu B, Gao H, Jiang Y, Luo D, Fu C, Zhao Z. The role of the A428D mutation in conferring resistance to pirtobrutinib in Bruton\u2019s tyrosine kinase: insights from molecular dynamics simulations. Res Chem. 2026;26:103346. https:\/\/doi.org\/10.1016\/j.rechem.2026.103346.","journal-title":"Res Chem"},{"key":"4474_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114611","volume":"241","author":"M Yang","year":"2022","unstructured":"Yang M, Jiang H, Yang Z, et al. Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton\u2019s tyrosine kinase (BTK) inhibitors. Eur J Med Chem. 2022;241:114611. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114611.","journal-title":"Eur J Med Chem"},{"key":"4474_CR49","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1182\/bloodadvances.2024015014","volume":"9","author":"N Ahmed","year":"2025","unstructured":"Ahmed N, Thiruvengadam SK, Hamadani M, et al. Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis. Blood Adv. 2025;9:5382\u201396. https:\/\/doi.org\/10.1182\/bloodadvances.2024015014.","journal-title":"Blood Adv"},{"key":"4474_CR50","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jtct.2025.06.013","volume":"31","author":"JC Chavez","year":"2025","unstructured":"Chavez JC, Hoffmann MS, Popplewell LL. Evaluating the role of CAR-T cell therapy in the context of current therapy options for patients with relapsed or refractory follicular lymphoma. Transp Cell Thera. 2025;31:639\u201354. https:\/\/doi.org\/10.1016\/j.jtct.2025.06.013.","journal-title":"Transp Cell Thera"},{"key":"4474_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100176","volume":"3","author":"JC Chavez","year":"2026","unstructured":"Chavez JC, Napier E, Bondanza A, et al. Tisagenlecleucel in combination with ibrutinib in adults with relapsed and\/or refractory large B-cell lymphomas. Blood Neoplasia. 2026;3:100176. https:\/\/doi.org\/10.1016\/j.bneo.2025.100176.","journal-title":"Blood Neoplasia"},{"key":"4474_CR52","doi-asserted-by":"publisher","first-page":"e421","DOI":"10.1016\/j.clml.2026.01.008","volume":"26","author":"JM Clement","year":"2026","unstructured":"Clement JM, Portell CA. SOHO state of the art updates and next questions|sequencing therapies in relapsed\/refractory mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2026;26:e421\u20139. https:\/\/doi.org\/10.1016\/j.clml.2026.01.008.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4474_CR53","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.hoc.2020.06.010","volume":"34","author":"J Gauthier","year":"2020","unstructured":"Gauthier J, Maloney DG. Allogeneic transplantation and chimeric antigen receptor-engineered T-Cell therapy for relapsed or refractory mantle cell lymphoma. Hematol Oncol Clin North Am. 2020;34:957\u201370. https:\/\/doi.org\/10.1016\/j.hoc.2020.06.010.","journal-title":"Hematol Oncol Clin North Am"},{"key":"4474_CR54","doi-asserted-by":"publisher","first-page":"S212","DOI":"10.1016\/S2152-2650(23)00775-9","volume":"23","author":"R Lakhotia","year":"2023","unstructured":"Lakhotia R, Pittaluga S, Phelan J, et al. POSTER: MCL-349 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed\/Refractory (R\/R) and treatment-Na\u00efve (TN) mantle cell lymphoma (MCL). Clin Lymphoma Myeloma Leuk. 2023;23:S212. https:\/\/doi.org\/10.1016\/S2152-2650(23)00775-9.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4474_CR55","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025031309","author":"P Marcoux","year":"2026","unstructured":"Marcoux P, Gava F, Tosolini M, et al. Patient-derived lymphoma spheroids reveal predictive markers of glofitamab resistance in relapsed\/refractory B-NHL. Blood. 2026. https:\/\/doi.org\/10.1182\/blood.2025031309.","journal-title":"Blood"},{"key":"4474_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2026.06.001","author":"ARYB Lee","year":"2026","unstructured":"Lee ARYB, Wong HJ, Lim CC, et al. Monospecific and bispecific chimeric antigen receptor (CAR) T-Cell therapy in multiple myeloma: a systematic review, meta-analysis and meta-regression. Transp Cell Thera. 2026. https:\/\/doi.org\/10.1016\/j.jtct.2026.06.001.","journal-title":"Transp Cell Thera"},{"key":"4474_CR57","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1182\/bloodadvances.2025015791","volume":"9","author":"L Meriranta","year":"2025","unstructured":"Meriranta L, Rask Kragh J\u00f8rgensen R, Pasanen A, et al. Circulating tumor DNA determinants of response and outcome in relapsed\/refractory mantle cell lymphoma. Blood Adv. 2025;9:4528\u201341. https:\/\/doi.org\/10.1182\/bloodadvances.2025015791.","journal-title":"Blood Adv"},{"key":"4474_CR58","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0140-6736(25)02435-3","volume":"407","author":"ML Palomba","year":"2026","unstructured":"Palomba ML, Schuster SJ, Karmali R, et al. Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study. The Lancet. 2026;407:963\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(25)02435-3.","journal-title":"The Lancet"},{"key":"4474_CR59","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1182\/bloodadvances.2025017160","volume":"10","author":"T Phillips","year":"2026","unstructured":"Phillips T, Di M, Miller TA, et al. Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed\/refractory mantle cell lymphoma. Blood Adv. 2026;10:1457\u201368. https:\/\/doi.org\/10.1182\/bloodadvances.2025017160.","journal-title":"Blood Adv"},{"key":"4474_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101221","volume":"67","author":"CE Ryan","year":"2024","unstructured":"Ryan CE, Kumar A. Dismantling relapsed\/refractory mantle cell lymphoma. Blood Rev. 2024;67:101221. https:\/\/doi.org\/10.1016\/j.blre.2024.101221.","journal-title":"Blood Rev"},{"key":"4474_CR61","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1182\/bloodadvances.2025016845","volume":"10","author":"JM Tuscano","year":"2026","unstructured":"Tuscano JM, Othman T, Frankel P, et al. A phase 1 study of blinatumomab\/lenalidomide in relapsed\/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis. Blood Adv. 2026;10:1153\u201362. https:\/\/doi.org\/10.1182\/bloodadvances.2025016845.","journal-title":"Blood Adv"},{"key":"4474_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellin.2026.100327","volume":"5","author":"R Yan","year":"2026","unstructured":"Yan R, Ye S, Xu H. Challenges and opportunities: CAR-T cell therapy in autoimmune diseases. Cell Insight. 2026;5:100327. https:\/\/doi.org\/10.1016\/j.cellin.2026.100327.","journal-title":"Cell Insight"},{"key":"4474_CR63","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.1182\/bloodadvances.2023009804","volume":"7","author":"D Villa","year":"2023","unstructured":"Villa D, Jiang A, Visco C, et al. Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed\/refractory mantle cell lymphoma. Blood Adv. 2023;7:4576\u201385. https:\/\/doi.org\/10.1182\/bloodadvances.2023009804.","journal-title":"Blood Adv"},{"key":"4474_CR64","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1182\/bloodadvances.2024015763","volume":"10","author":"Y Xie","year":"2026","unstructured":"Xie Y, Zhou K-S, Li L-F, et al. Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed\/refractory mantle cell lymphoma in Chinese adults. Blood Adv. 2026;10:1134\u201344. https:\/\/doi.org\/10.1182\/bloodadvances.2024015763.","journal-title":"Blood Adv"},{"key":"4474_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107519","volume":"142","author":"B Yaniv","year":"2024","unstructured":"Yaniv B, Tanenbaum B, Kazakova V, Patel SA. Translational insights into the genetics and immunobiology of relapsed\/refractory follicular lymphoma. Leuk Res. 2024;142:107519. https:\/\/doi.org\/10.1016\/j.leukres.2024.107519.","journal-title":"Leuk Res"},{"key":"4474_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102131","author":"PL Zinzani","year":"2023","unstructured":"Zinzani PL, Trn\u011bn\u00fd M, Ribrag V, et al. Parsaclisib a PI3K\u03b4 inhibitor in relapsed and refractory mantle cell lymphoma (CITADEL-205) a phase 2 study. eClinicalMedicine. 2023. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102131.","journal-title":"eClinicalMedicine"},{"key":"4474_CR67","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025032422","author":"LE Budde","year":"2026","unstructured":"Budde LE, Kamdar M, Assouline SE, et al. Mosunetuzumab plus polatuzumab vedotin in relapsed\/refractory MCL after BTK inhibitor therapy: a phase 2 study. Blood. 2026. https:\/\/doi.org\/10.1182\/blood.2025032422.","journal-title":"Blood"},{"key":"4474_CR68","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.beha.2016.08.011","volume":"29","author":"JE Castro","year":"2016","unstructured":"Castro JE, Kipps TJ. Adoptive cellular therapy for chronic lymphocytic leukemia and B cell malignancies. CARs and more. Best Pract Res Clini Haematol. 2016;29:15\u201329. https:\/\/doi.org\/10.1016\/j.beha.2016.08.011.","journal-title":"Best Pract Res Clini Haematol"},{"key":"4474_CR69","doi-asserted-by":"publisher","first-page":"5654","DOI":"10.1182\/bloodadvances.2025016315","volume":"9","author":"ZD Epstein-Peterson","year":"2025","unstructured":"Epstein-Peterson ZD, Lionel AC, Joseph A, et al. Treatment and outcomes of progression of disease post\u2013CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis. Blood Adv. 2025;9:5654\u201362. https:\/\/doi.org\/10.1182\/bloodadvances.2025016315.","journal-title":"Blood Adv"},{"key":"4474_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2026.115213","author":"KJ Hern\u00e1ndez-Idarraga","year":"2026","unstructured":"Hern\u00e1ndez-Idarraga KJ, Arias-Rozo AJ, Arango-Rodr\u00edguez ML, Sossa CL, Becerra-Bayona SM. CAR T-cells in hematologic malignancies: advances, challenges, and future directions. iScience. 2026. https:\/\/doi.org\/10.1016\/j.isci.2026.115213.","journal-title":"iScience"},{"key":"4474_CR71","doi-asserted-by":"publisher","first-page":"105597","DOI":"10.1016\/j.ebiom.2025.105597","volume":"113","author":"A Murias-Closas","year":"2025","unstructured":"Murias-Closas A, Prats C, Calvo G, L\u00f3pez-Codina D, Olesti E. Computational modelling of CAR T-cell therapy: from cellular kinetics to patient-level predictions. EBioMedicine. 2025;113:105597. https:\/\/doi.org\/10.1016\/j.ebiom.2025.105597.","journal-title":"EBioMedicine"},{"key":"4474_CR72","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1182\/blood-2023-186203","volume":"142","author":"J Chen","year":"2023","unstructured":"Chen J, Cui Q, Li M, et al. Application of cfDNA-NGS test in MRD monitoring of acute leukemia patients with CAR-T cell therapy. Blood. 2023;142:2282. https:\/\/doi.org\/10.1182\/blood-2023-186203.","journal-title":"Blood"},{"key":"4474_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101272","volume":"71","author":"S Pagliuca","year":"2025","unstructured":"Pagliuca S, Malard F, Mooyaart JE, et al. The landscape of immune monitoring in CAR-T cell therapy: a comprehensive review and survey study by the cellular therapy and immunobiology working party of the EBMT. Blood Rev. 2025;71:101272. https:\/\/doi.org\/10.1016\/j.blre.2025.101272.","journal-title":"Blood Rev"},{"key":"4474_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2026.101125","volume":"47","author":"MK Posa","year":"2026","unstructured":"Posa MK, Singh J, Parveen S, Panda S. CAR T- cell therapy: a promising novel approach for treatment of cancer. Cancer Treat Res CommuniC. 2026;47:101125. https:\/\/doi.org\/10.1016\/j.ctarc.2026.101125.","journal-title":"Cancer Treat Res CommuniC"},{"key":"4474_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2026.04.004","author":"MA Soomro","year":"2026","unstructured":"Soomro MA, Ahmed M, Abdallah AO, Ahmed N, Kort J. Resistance to BCMA-directed CAR T-cell therapy in multiple myeloma: biology, clinical patterns, and strategies to overcome treatment failure. Clin Lymphoma Myeloma Leuk. 2026. https:\/\/doi.org\/10.1016\/j.clml.2026.04.004.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4474_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.nexres.2025.100892","volume":"2","author":"A Unni","year":"2025","unstructured":"Unni A, Ragavendra SP. Engineering T cells for cancer: the evolution and future of CAR-based therapies. Next Res. 2025;2:100892. https:\/\/doi.org\/10.1016\/j.nexres.2025.100892.","journal-title":"Next Res"},{"key":"4474_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102555","volume":"62","author":"S Yan","year":"2025","unstructured":"Yan S, Zhu X, Xiao Y. CD70-targeted CAR-T\/NK therapy: rationale, advances, and future directions. Transl Oncol. 2025;62:102555. https:\/\/doi.org\/10.1016\/j.tranon.2025.102555.","journal-title":"Transl Oncol"},{"key":"4474_CR78","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jtct.2021.01.026","volume":"27","author":"F Yassine","year":"2021","unstructured":"Yassine F, Sandoval-Sus J, Ayala E, Chavez J, Hamadani M, Kharfan-Dabaja MA. Cellular therapies for mantle cell lymphoma. Transp Cell Thera. 2021;27:363\u201370. https:\/\/doi.org\/10.1016\/j.jtct.2021.01.026.","journal-title":"Transp Cell Thera"},{"key":"4474_CR79","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1182\/blood.2025030872","volume":"147","author":"AY Ge","year":"2026","unstructured":"Ge AY, Feldman WB, Kaiser MF, et al. Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries. Blood. 2026;147:1521\u201331. https:\/\/doi.org\/10.1182\/blood.2025030872.","journal-title":"Blood"},{"key":"4474_CR80","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.jcyt.2025.08.005","volume":"27","author":"WYK Hwang","year":"2025","unstructured":"Hwang WYK, Bari S, Kawamata S, et al. Cell and gene therapy approvals in Asia: regulatory landscape, access and affordability. Cytotherapy. 2025;27:1363\u201374. https:\/\/doi.org\/10.1016\/j.jcyt.2025.08.005.","journal-title":"Cytotherapy"},{"key":"4474_CR81","doi-asserted-by":"publisher","first-page":"S188","DOI":"10.1016\/j.jtct.2025.12.259","volume":"32","author":"R Thakur","year":"2026","unstructured":"Thakur R, Betts BC, Holtan S, et al. Liquid MRD detection using circulating myeloma cells accurately reflects bone marrow disease status Post\u2013CAR T and ASCT. Transp Cell Thera. 2026;32:S188. https:\/\/doi.org\/10.1016\/j.jtct.2025.12.259.","journal-title":"Transp Cell Thera"},{"key":"4474_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ordal.2025.200478","volume":"45","author":"M\u00c1 Vecina","year":"2025","unstructured":"Vecina M\u00c1, Villa F, Vallada E, Karpova Y. Enhancing management efficiency in emergency vehicles logistic using realistic data from geographic information system. Oper Res, Data Anal Logist. 2025;45:200478. https:\/\/doi.org\/10.1016\/j.ordal.2025.200478.","journal-title":"Oper Res, Data Anal Logist"},{"key":"4474_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.psep.2025.107980","volume":"203","author":"AI Yunus","year":"2025","unstructured":"Yunus AI, Igou T, Jalla S, et al. Per- and polyfluoroalkyl substances (PFAS) in resource recovery: transforming challenges into opportunities for sustainable nutrients and biosolids management. Process Saf Environ Prot. 2025;203:107980. https:\/\/doi.org\/10.1016\/j.psep.2025.107980.","journal-title":"Process Saf Environ Prot"},{"key":"4474_CR84","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.clml.2024.06.006","volume":"24","author":"M Colton","year":"2024","unstructured":"Colton M, Purev E, Haverkos B, et al. Molecular disease monitoring in patients with Relapsed\/refractory B-Cell lymphoma receiving Anti-CD19 CAR T-Cell therapy. Clin Lymphoma Myeloma Leuk. 2024;24:778\u201382. https:\/\/doi.org\/10.1016\/j.clml.2024.06.006.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4474_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2026.105065","volume":"419","author":"L He","year":"2026","unstructured":"He L, Liu Y, Zhou J, et al. Ibrutinib enhances stem-cell-memory T cell generation during early T cell activation but inhibits T cell proliferation. Cell Immunol. 2026;419:105065. https:\/\/doi.org\/10.1016\/j.cellimm.2026.105065.","journal-title":"Cell Immunol"},{"key":"4474_CR86","doi-asserted-by":"publisher","first-page":"676.e671","DOI":"10.1016\/j.jtct.2026.02.058","volume":"32","author":"M Gomez-Llobell","year":"2026","unstructured":"Gomez-Llobell M, Shouval R, Brown S, et al. Landmark-based evaluations of long-term outcomes after CD19 CAR T-cell therapy in Large B-cell lymphoma. Transp Cell Thera. 2026;32:676.e671-676.e614. https:\/\/doi.org\/10.1016\/j.jtct.2026.02.058.","journal-title":"Transp Cell Thera"},{"key":"4474_CR87","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.pathol.2025.11.016","volume":"58","author":"W-w Zhang","year":"2026","unstructured":"Zhang W-w, Ke L-f, Wu C-y, et al. Immune receptor translocation-associated protein 1 and myeloid nuclear differentiation antigen are useful markers for the differential diagnosis of marginal zone lymphoma. Pathology. 2026;58:432\u20138. https:\/\/doi.org\/10.1016\/j.pathol.2025.11.016.","journal-title":"Pathology"},{"key":"4474_CR88","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025019336","author":"H Parker","year":"2026","unstructured":"Parker H, Mirandari A, Stevens B, et al. Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevance. Blood Adv. 2026. https:\/\/doi.org\/10.1182\/bloodadvances.2025019336.","journal-title":"Blood Adv"},{"key":"4474_CR89","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/S0140-6736(26)00362-4","volume":"407","author":"M Dreyling","year":"2026","unstructured":"Dreyling M, Doorduijn J, Gin\u00e9 E, et al. Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18\u201365 years with mantle cell lymphoma (TRIANGLE): 4\u00b75-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network. The Lancet. 2026;407:1953\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(26)00362-4.","journal-title":"The Lancet"},{"key":"4474_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2026.05.102","author":"Z Wang","year":"2026","unstructured":"Wang Z, Ba C, Zhu H, Chen Z, Chen C, Qian S. Single-cell analyses redefine cell heterogeneity signatures in diffuse large B-cell lymphoma and follicular lymphoma: Molecular insights and clinical impacts. J Formos Med Assoc. 2026. https:\/\/doi.org\/10.1016\/j.jfma.2026.05.102.","journal-title":"J Formos Med Assoc"},{"key":"4474_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2026.100219","volume":"3","author":"SM Gholy","year":"2026","unstructured":"Gholy SM, Ranad\u00f3ttir T, Davidsson OB, et al. CD20 negativity at the start of second-line therapy predicts a shorter overall survival in B-cell lymphomas. Blood Neoplasia. 2026;3:100219. https:\/\/doi.org\/10.1016\/j.bneo.2026.100219.","journal-title":"Blood Neoplasia"},{"key":"4474_CR92","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2026033577","author":"X Gong","year":"2026","unstructured":"Gong X, Liu Y, Fang Q, et al. Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia. Blood. 2026. https:\/\/doi.org\/10.1182\/blood.2026033577.","journal-title":"Blood"},{"key":"4474_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.bglo.2026.100097","author":"PdS Perez","year":"2026","unstructured":"Perez PdS, de Souza Santos FP, Queiroz RR, et al. Venetoclax for Unfit AML: real-world outcomes of standard and azole-adjusted dosing in brazilian public and private care. Blood Global Hematol. 2026. https:\/\/doi.org\/10.1016\/j.bglo.2026.100097.","journal-title":"Blood Global Hematol"},{"key":"4474_CR94","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.neuroscience.2018.04.037","volume":"382","author":"MP Jankowski","year":"2018","unstructured":"Jankowski MP, Miller L, Koerber HR. Increased expression of transcription factor SRY-box-containing gene 11 (Sox11) enhances neurite growth by regulating neurotrophic factor responsiveness. Neuroscience. 2018;382:93\u2013104. https:\/\/doi.org\/10.1016\/j.neuroscience.2018.04.037.","journal-title":"Neuroscience"},{"key":"4474_CR95","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.3324\/haematol.2025.288185","volume":"111","author":"Z Loh","year":"2026","unstructured":"Loh Z, Yeh P, Keane C, Hawkes EA. Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies. Haematologica. 2026;111:1198\u2013214. https:\/\/doi.org\/10.3324\/haematol.2025.288185.","journal-title":"Haematologica"},{"key":"4474_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2026.201231","volume":"34","author":"G Escobar","year":"2026","unstructured":"Escobar G, Maus MV. Optimizing CAR T cell therapy in pancreatic cancer through clinically actionable combinations. Mol Thera Oncol. 2026;34:201231. https:\/\/doi.org\/10.1016\/j.omton.2026.201231.","journal-title":"Mol Thera Oncol"},{"key":"4474_CR97","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.freeradbiomed.2025.12.028","volume":"244","author":"Z Li","year":"2026","unstructured":"Li Z, Shi X, Wang F, Wu X, Gong J, Kang Q. Fucoidan potentiates CAR NK cell-mediated antitumor efficacy against non-Hodgkin lymphoma via NRF2. Free Radical Biol Med. 2026;244:496\u2013504. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2025.12.028.","journal-title":"Free Radical Biol Med"},{"key":"4474_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2026.106449","volume":"48","author":"M Milanesio","year":"2026","unstructured":"Milanesio M, Berro M, Vitriu A, et al. Real-world data of autologous stem cell transplantation for patients with mantle cell lymphoma in Argentina. Hematol, Transfus Cell Thera. 2026;48:106449. https:\/\/doi.org\/10.1016\/j.htct.2026.106449.","journal-title":"Hematol, Transfus Cell Thera"},{"key":"4474_CR99","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.3324\/haematol.2025.288929","volume":"111","author":"L Jiang","year":"2026","unstructured":"Jiang L, Ladetto M, Hermine O, et al. Marked survival gains in patients \u2264 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996\u20132020. Haematologica. 2026;111:1694\u2013704. https:\/\/doi.org\/10.3324\/haematol.2025.288929.","journal-title":"Haematologica"},{"key":"4474_CR100","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.cmi.2025.10.005","volume":"32","author":"A Bouvier","year":"2026","unstructured":"Bouvier A, Durand A, Dupont V, et al. Invasive fungal infections after CD19 chimeric antigen receptor T-cell therapy for B-cell lymphoma: a lymphoma study association study from the DESCAR-T (Dispositif d\u2019Enregistrement et Suivi des patients trait\u00e9s par CAR-T cells) registry. Clin Microbiol Infect. 2026;32:277\u201384. https:\/\/doi.org\/10.1016\/j.cmi.2025.10.005.","journal-title":"Clin Microbiol Infect"},{"key":"4474_CR101","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1182\/bloodadvances.2025016765","volume":"10","author":"N Li","year":"2026","unstructured":"Li N, Liu Y, Zhang L, et al. Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma. Blood Adv. 2026;10:1722\u201332. https:\/\/doi.org\/10.1182\/bloodadvances.2025016765.","journal-title":"Blood Adv"},{"key":"4474_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.sycrs.2025.100152","volume":"7","author":"IA Shaikh","year":"2026","unstructured":"Shaikh IA, Rasheed A, Ali SF, Aslam M, Zia S, Iftikhar H. Primary nasopharyngeal germinal center diffuse large B cell lymphoma (DLBCL) presenting with multiple cranial neuropathies and skull base invasion: a case report. Surgery Case Rep. 2026;7:100152. https:\/\/doi.org\/10.1016\/j.sycrs.2025.100152.","journal-title":"Surgery Case Rep"},{"key":"4474_CR103","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.ymthe.2025.10.046","volume":"34","author":"Z Riester","year":"2026","unstructured":"Riester Z, Surowka M, Seifert N, et al. Co-expression of an adapter CAR retains efficacy of CAR T cells after single and dual antigen loss in lymphoma. Mol Ther. 2026;34:867\u201384. https:\/\/doi.org\/10.1016\/j.ymthe.2025.10.046.","journal-title":"Mol Ther"},{"key":"4474_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2026.106367","volume":"11","author":"D Synnott","year":"2026","unstructured":"Synnott D, Bowden A, Sexton DJ. Systematic review of immunosuppression after chimeric antigen receptor t-cell therapy for posttransplant lymphoproliferative disorder. Kidney Int Rep. 2026;11:106367. https:\/\/doi.org\/10.1016\/j.ekir.2026.106367.","journal-title":"Kidney Int Rep"},{"key":"4474_CR105","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016688","author":"R Xu","year":"2026","unstructured":"Xu R, Wu G, Rice S, et al. Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy. Blood Adv. 2026. https:\/\/doi.org\/10.1182\/bloodadvances.2025016688.","journal-title":"Blood Adv"},{"key":"4474_CR106","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1021\/acschembio.5c00913","volume":"21","author":"SE Ayscough","year":"2026","unstructured":"Ayscough SE, Clifton LA, \u00c5d\u00e9n J, et al. Avoiding mitochondrial apoptosis by the Bcl-2-driven Bax oligomerization on membrane surfaces. ACS Chem Biol. 2026;21:565\u201376. https:\/\/doi.org\/10.1021\/acschembio.5c00913.","journal-title":"ACS Chem Biol"},{"key":"4474_CR107","unstructured":"Mellor CEL, Gilmore AP. Proximity biotin labelling identification (BioID) analysis of Bcl-2 protein interactions in live cells. Methods in Cell Biology: Academic Press; 2026."},{"key":"4474_CR108","doi-asserted-by":"publisher","first-page":"10897","DOI":"10.1021\/acs.jmedchem.4c03083","volume":"68","author":"D Zhang","year":"2025","unstructured":"Zhang D, Zhao J, Xu G, et al. Discovery of Imidazo [1,2-b]pyridazine derivatives as Potent and highly selective irreversible Bruton\u2019s tyrosine kinase (BTK) inhibitors. J Med Chem. 2025;68:10897\u2013929. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c03083.","journal-title":"J Med Chem"},{"key":"4474_CR109","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c03212","author":"Y Li","year":"2026","unstructured":"Li Y, Fu S, Yang J, et al. Acrylamide bioisosterism: alkenyl aromatic heterocycles as reactivity-tunable warheads for covalent BTK inhibitors. J Med Chem. 2026. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c03212.","journal-title":"J Med Chem"},{"key":"4474_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118308","volume":"189","author":"S Ashique","year":"2025","unstructured":"Ashique S, Debnath B, Ramzan M, et al. A critical review of the synergistic potential of targeting p53 and CAR T cell therapy in cancer treatment. Biomed Pharmacother. 2025;189:118308. https:\/\/doi.org\/10.1016\/j.biopha.2025.118308.","journal-title":"Biomed Pharmacother"},{"key":"4474_CR111","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.32604\/biocell.2025.067216","volume":"49","author":"SC Diamantoudis","year":"2025","unstructured":"Diamantoudis SC, Miliotou AN, Galatou E, et al. Assessing the hematological cancer stem cell landscape to improve immunotherapy clinical decisions. Biocell. 2025;49:1799\u2013858. https:\/\/doi.org\/10.32604\/biocell.2025.067216.","journal-title":"Biocell"},{"key":"4474_CR112","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5c00773","author":"BD Hornsby","year":"2025","unstructured":"Hornsby BD, Tuekpe JKK, Steele CA, Devereaux AA, Bowman KER, Lim CS. Mitochondrially targeted p53-Bad* fusion gene therapy promotes apoptosis in hepatocellular carcinoma by Pan-Bcl-2 inhibition. Mol Pharm. 2025. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c00773.","journal-title":"Mol Pharm"},{"key":"4474_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2026.e44991","volume":"12","author":"A Valizadeh","year":"2026","unstructured":"Valizadeh A, Rahmati-Yamchi M, Alihemmati A, Yousefi B. PI3K\/Akt\/mTOR signaling pathway: a critical signal transduction pathway in the anti-cancer effects of resveratrol. Heliyon. 2026;12:e44991. https:\/\/doi.org\/10.1016\/j.heliyon.2026.e44991.","journal-title":"Heliyon"},{"key":"4474_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/medsci13040275","author":"K Girigoswami","year":"2025","unstructured":"Girigoswami K, Girigoswami A. Breast cancer progression and its theranostic management via folate-directed targeting of glycoprotein receptor. Med Sci (Basel). 2025. https:\/\/doi.org\/10.3390\/medsci13040275.","journal-title":"Med Sci (Basel)"},{"key":"4474_CR115","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202500676","volume":"27","author":"MS Shaikh","year":"2026","unstructured":"Shaikh MS, Kurhade RR, Siddiqui AA, et al. Advancements in targeted radiopharmaceuticals: innovations in diagnosis and therapy for enhanced cancer management. ChemBioChem. 2026;27:e202500676.","journal-title":"ChemBioChem"},{"key":"4474_CR116","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S568254","author":"V Gupta","year":"2026","unstructured":"Gupta V, Kumar D, Gupta S, et al. Nanotechnology-driven cancer therapies for precision oncology: advances and clinical outlook. Int J Nanomed. 2026. https:\/\/doi.org\/10.2147\/IJN.S568254.","journal-title":"Int J Nanomed"},{"key":"4474_CR117","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1021\/acs.molpharmaceut.5c01219","volume":"23","author":"J Zhao","year":"2026","unstructured":"Zhao J, Xie Q, Peng Y, et al. 131I-Labeled dual immune checkpoint inhibitors for tumor microenvironment improvement to enhance antitumor efficacy. Mol Pharm. 2026;23:844\u201358. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c01219.","journal-title":"Mol Pharm"},{"key":"4474_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2026.103027","volume":"115","author":"G Fan","year":"2026","unstructured":"Fan G, Zhang Q, Guo W, et al. Proteolysis-targeting chimera (PROTAC): A promising senolytic strategy. Ageing Res Rev. 2026;115:103027. https:\/\/doi.org\/10.1016\/j.arr.2026.103027.","journal-title":"Ageing Res Rev"},{"key":"4474_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2026.105040","volume":"146","author":"J Wang","year":"2026","unstructured":"Wang J, Xu J, Ma X, et al. Epigenetic therapy combined with radiotherapy reshapes tumor immune response. Exp Mol Pathol. 2026;146:105040. https:\/\/doi.org\/10.1016\/j.yexmp.2026.105040.","journal-title":"Exp Mol Pathol"},{"key":"4474_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.genrep.2025.102296","volume":"40","author":"S Abbas","year":"2025","unstructured":"Abbas S, Saeed A, Bibi M, Perveen S, Masood N. CRISPR-Cas: From bacterial immunity to precision genome engineering. Gene Reports. 2025;40:102296. https:\/\/doi.org\/10.1016\/j.genrep.2025.102296.","journal-title":"Gene Reports"},{"key":"4474_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2026.108187","volume":"227","author":"R Roskoski","year":"2026","unstructured":"Roskoski R. Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders. Pharmacol Res. 2026;227:108187. https:\/\/doi.org\/10.1016\/j.phrs.2026.108187.","journal-title":"Pharmacol Res"},{"key":"4474_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(25)00374-1","author":"M \u00d8stergaard","year":"2026","unstructured":"\u00d8stergaard M, Haavardsholm EA, Nowak M, et al. Efficacy and safety of branebrutinib (BMS-986195), an irreversible Bruton\u2019s tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2a, randomised, double-blind, placebo-controlled study. Lancet Rheumatol. 2026. https:\/\/doi.org\/10.1016\/S2665-9913(25)00374-1.","journal-title":"Lancet Rheumatol"},{"key":"4474_CR123","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1021\/acs.jmedchem.5c02785","volume":"69","author":"G Liu","year":"2026","unstructured":"Liu G, Liu S, Cho S, et al. Strategic use of benzylic alcohols reveals cryptic hydrogen-bonding interactions: discovery of hbc-12551 as a potent noncovalent Bruton\u2019s tyrosine kinase inhibitor. J Med Chem. 2026;69:2867\u201387. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c02785.","journal-title":"J Med Chem"},{"key":"4474_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2026.156491","volume":"283","author":"Z Jiang","year":"2026","unstructured":"Jiang Z, Liu L, Tang J, Chen X. PI3K\/Akt\/mTOR signaling pathway: The major signal transduction involved in the anticancer effects of resveratrol. Pathol\u2014Res Prac. 2026;283:156491. https:\/\/doi.org\/10.1016\/j.prp.2026.156491.","journal-title":"Pathol\u2014Res Prac"},{"key":"4474_CR125","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1182\/blood.2025031156","volume":"147","author":"X Li","year":"2026","unstructured":"Li X, Liu M, Shi Q, et al. CSNK1E sustains stemlike drug persistence in diffuse large B-cell lymphoma. Blood. 2026;147:2633\u201347. https:\/\/doi.org\/10.1182\/blood.2025031156.","journal-title":"Blood"},{"key":"4474_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2026.118133","volume":"251","author":"Y Ma","year":"2026","unstructured":"Ma Y, Tian Y, Wang H, et al. Targeting CDK4 with repurposing perphenazine inhibited the growth of gastric cancer AGS and HGC27 cells by arresting cell cycle. Biochem Pharmacol. 2026;251:118133. https:\/\/doi.org\/10.1016\/j.bcp.2026.118133.","journal-title":"Biochem Pharmacol"},{"key":"4474_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2026.118932","volume":"315","author":"X Lv","year":"2026","unstructured":"Lv X, Huang X, Tian L, et al. CADD-based discovery of novel heterocyclic pyrimidine-based CDK4\/6 inhibitors: Design, synthesis, and anti-breast cancer activity studies. Eur J Med Chem. 2026;315:118932. https:\/\/doi.org\/10.1016\/j.ejmech.2026.118932.","journal-title":"Eur J Med Chem"},{"key":"4474_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2026.108141","volume":"226","author":"N Zeng","year":"2026","unstructured":"Zeng N, Zhong X-Y, Zhang S-H, et al. Proteolysis-targeting chimeras induce ferroptosis in cancer: from mechanism to clinical application. Pharmacol Res. 2026;226:108141. https:\/\/doi.org\/10.1016\/j.phrs.2026.108141.","journal-title":"Pharmacol Res"},{"key":"4474_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114591","volume":"391","author":"G Rong","year":"2026","unstructured":"Rong G, Li Y, Zhu F, et al. Dual-targeting fluorous peptide proteolysis-targeting chimeras for cancer therapy. J Control Release. 2026;391:114591. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114591.","journal-title":"J Control Release"},{"key":"4474_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2026.118982","volume":"315","author":"S Huang","year":"2026","unstructured":"Huang S, Lv Y, Wang Y, et al. Targeted degradation of SETDB1 by an aptamer-CRBNL PROTAC as a novel therapeutic strategy for breast cancer. Eur J Med Chem. 2026;315:118982. https:\/\/doi.org\/10.1016\/j.ejmech.2026.118982.","journal-title":"Eur J Med Chem"},{"key":"4474_CR131","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.chembiol.2026.01.008","volume":"33","author":"B Li","year":"2026","unstructured":"Li B, Li Y, Zhang J, et al. Lysosome-targeting chimeras enable targeted protein degradation. Cell Chem Biol. 2026;33:433\u201360. https:\/\/doi.org\/10.1016\/j.chembiol.2026.01.008.","journal-title":"Cell Chem Biol"},{"key":"4474_CR132","doi-asserted-by":"publisher","first-page":"8688","DOI":"10.1021\/acs.jmedchem.5c03330","volume":"69","author":"W Peng","year":"2026","unstructured":"Peng W, Pan X, Wang S, Huang G, Qian Y. New PROTAC designs for targeted protein degradation in 2021\u20132025: Novel E3 ligases and Pre-PROTACs. J Med Chem. 2026;69:8688\u2013718. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c03330.","journal-title":"J Med Chem"},{"key":"4474_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105384","volume":"224","author":"J Gu","year":"2026","unstructured":"Gu J, He M, Wang W, et al. Exploiting CD36 as a self-facilitated endocytic receptor for PROTAC-mediated protein degradation: A new paradigm in cancer therapy. Crit Rev Oncol Hematol. 2026;224:105384. https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105384.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4474_CR134","doi-asserted-by":"publisher","first-page":"6491","DOI":"10.1182\/bloodadvances.2025016117","volume":"9","author":"A Dodero","year":"2025","unstructured":"Dodero A, Ceparano G, Casadei B, et al. Outcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis. Blood Adv. 2025;9:6491\u2013501. https:\/\/doi.org\/10.1182\/bloodadvances.2025016117.","journal-title":"Blood Adv"},{"key":"4474_CR135","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1182\/bloodadvances.2025016727","volume":"10","author":"F Erbella","year":"2026","unstructured":"Erbella F, Bachy E, Cartron G, et al. Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry. Blood Adv. 2026;10:392\u2013401. https:\/\/doi.org\/10.1182\/bloodadvances.2025016727.","journal-title":"Blood Adv"},{"key":"4474_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2026.04.003","author":"S Escribano Serrat","year":"2026","unstructured":"Escribano Serrat S, Ip A, Sanz J, et al. Outcomes of salvage therapy after early-line CD19 chimeric antigen receptor T-cell failure in large B-cell lymphoma. Transp Cell Thera. 2026. https:\/\/doi.org\/10.1016\/j.jtct.2026.04.003.","journal-title":"Transp Cell Thera"},{"key":"4474_CR137","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.clml.2024.07.020","volume":"25","author":"U Goel","year":"2025","unstructured":"Goel U, Mian A, Sauter CS. SOHO State of the art updates and next questions|contemporary role of autologous stem cell transplantation for the treatment of relapsed\/refractory diffuse large b-cell lymphoma in the era of cellular therapies. Clin Lymphoma Myeloma Leuk. 2025;25:219\u201325. https:\/\/doi.org\/10.1016\/j.clml.2024.07.020.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4474_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2026.02.058","author":"M Gomez-Llobell","year":"2026","unstructured":"Gomez-Llobell M, Shouval R, Brown S, et al. Landmark-based evaluations of long-term outcomes after CD19 CAR T-cell therapy in large B-cell lymphoma. Transp CellThera. 2026. https:\/\/doi.org\/10.1016\/j.jtct.2026.02.058.","journal-title":"Transp CellThera"},{"key":"4474_CR139","doi-asserted-by":"publisher","first-page":"4924","DOI":"10.1182\/bloodadvances.2025016661","volume":"9","author":"A Gutierrez","year":"2025","unstructured":"Gutierrez A, Zeberio I, Pe\u00f1alver FJ, et al. Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO. Blood Adv. 2025;9:4924\u201335. https:\/\/doi.org\/10.1182\/bloodadvances.2025016661.","journal-title":"Blood Adv"},{"key":"4474_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105181","volume":"220","author":"P Loap","year":"2026","unstructured":"Loap P, Sarkozy C, Dendale R, Kirova Y. Optimizing bridging radiotherapy prior to CAR-T cell therapy: an evidence-based approach. Crit Rev Oncol Hematol. 2026;220:105181. https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105181.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4474_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2026.101301","author":"MS Mannan","year":"2026","unstructured":"Mannan MS, Musheer A, Khan MW, Abbas H, Jillani SAQ, Shan HA. BCMA-directed CAR-T cell therapy in relapsed\/refractory multiple myeloma: efficacy, safety survival, and future directions\u2014a systematic review and meta-analysis. J Curr Probl Cancer. 2026. https:\/\/doi.org\/10.1016\/j.currproblcancer.2026.101301.","journal-title":"J Curr Probl Cancer"},{"key":"4474_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104803","volume":"213","author":"W Ouyang","year":"2025","unstructured":"Ouyang W, Mi J-Q. Challenges facing CAR T-cell immunotherapy in multiple myeloma. Crit Rev Oncol Hematol. 2025;213:104803. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104803.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4474_CR143","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1182\/bloodadvances.2024015719","volume":"9","author":"E Shumilov","year":"2025","unstructured":"Shumilov E, Scholz JK, Seib M, et al. Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed\/refractory large B-cell lymphoma. Blood Adv. 2025;9:3955\u201366. https:\/\/doi.org\/10.1182\/bloodadvances.2024015719.","journal-title":"Blood Adv"},{"key":"4474_CR144","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2026.04.018","author":"RJ Summers","year":"2026","unstructured":"Summers RJ, Newman H, Teachey DT. SOHO state of the art updates and next questions | novel therapies in T-ALL: from CAR-T to novel targets. Clin Lymphoma Myeloma Leuk. 2026. https:\/\/doi.org\/10.1016\/j.clml.2026.04.018.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4474_CR145","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.synbio.2026.04.012","volume":"14","author":"D-Y Sun","year":"2026","unstructured":"Sun D-Y, Wang J-L, Li X, Wang S. Remodeling memory T cells with chemotherapy and immune checkpoint inhibitors as host pre-conditioning to empower in vivo CAR-T therapy. Synth Sys Biotechnol. 2026;14:155\u201370. https:\/\/doi.org\/10.1016\/j.synbio.2026.04.012.","journal-title":"Synth Sys Biotechnol"},{"key":"4474_CR146","doi-asserted-by":"publisher","first-page":"e365","DOI":"10.1016\/S2352-3026(25)00048-1","volume":"12","author":"J Xia","year":"2025","unstructured":"Xia J, Sun Q, Zhou D, et al. Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2025;12:e365\u201375. https:\/\/doi.org\/10.1016\/S2352-3026(25)00048-1.","journal-title":"Lancet Haematol"},{"key":"4474_CR147","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jtct.2025.06.018","volume":"31","author":"M Zuber","year":"2025","unstructured":"Zuber M, Elshafie S, Taj S, Villa ZL. Real-world treatment patterns and out-of-pocket costs after CAR T-cell therapy in commercially insured patients with B-Cell Non-Hodgkin lymphoma in the United States. Transp and Cell Thera. 2025;31:701\u20138. https:\/\/doi.org\/10.1016\/j.jtct.2025.06.018.","journal-title":"Transp and Cell Thera"},{"key":"4474_CR148","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.ymthe.2025.02.035","volume":"33","author":"TLA Wachsmann","year":"2025","unstructured":"Wachsmann TLA, Poortvliet T, Meeuwsen MH, et al. CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells. Mol Ther. 2025;33:1642\u201358. https:\/\/doi.org\/10.1016\/j.ymthe.2025.02.035.","journal-title":"Mol Ther"},{"key":"4474_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2026.218240","volume":"639","author":"L Si","year":"2026","unstructured":"Si L, Wei D, Pan J, Baleeiro RB, Chard Dunmall LS, Wang Y. CAR-T cell exhaustion in cancer over the past decade: mitochondrial metabolism as a target for counteraction. Cancer Lett. 2026;639:218240. https:\/\/doi.org\/10.1016\/j.canlet.2026.218240.","journal-title":"Cancer Lett"},{"key":"4474_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217771","volume":"626","author":"Y-T Bao","year":"2025","unstructured":"Bao Y-T, Lv M, Huang X-J, Zhao X-Y. The mechanisms and countermeasures for CAR-T cell expansion and persistence deficiency. Cancer Lett. 2025;626:217771. https:\/\/doi.org\/10.1016\/j.canlet.2025.217771.","journal-title":"Cancer Lett"},{"key":"4474_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189481","author":"E Skouradaki","year":"2025","unstructured":"Skouradaki E, Eptaminitaki GC, Kirio E, Zaravinos A, Dovrolis N, Baritaki S. RKIP and tumor immune evasion: remodeling the immunosuppressive tumor microenvironment. Biochimica et Biophysica Acta BBA Rev Cancer. 2025. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189481.","journal-title":"Biochimica et Biophysica Acta BBA Rev Cancer"},{"key":"4474_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2026.117949","volume":"250","author":"J Wu","year":"2026","unstructured":"Wu J, Li D, Mei H, Hu Y. Crosstalk between cytokines and tryptophan metabolism: Therapeutic potential for immune effector cell-associated neurotoxicity syndrome. Biochem Pharmacol. 2026;250:117949. https:\/\/doi.org\/10.1016\/j.bcp.2026.117949.","journal-title":"Biochem Pharmacol"},{"key":"4474_CR153","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S1470-2045(24)00715-0","volume":"26","author":"CE Graham","year":"2025","unstructured":"Graham CE, Velasco R, Alarcon Tomas A, et al. Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee. Lancet Oncol. 2025;26:e203\u201313. https:\/\/doi.org\/10.1016\/S1470-2045(24)00715-0.","journal-title":"Lancet Oncol"},{"key":"4474_CR154","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025032268","author":"H Sun","year":"2026","unstructured":"Sun H, Sklavenitis-Pistofidis R, Liu S, et al. Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenstr\u00f6m macroglobulinemia. Blood. 2026. https:\/\/doi.org\/10.1182\/blood.2025032268.","journal-title":"Blood"},{"key":"4474_CR155","doi-asserted-by":"publisher","first-page":"788.e781","DOI":"10.1016\/j.jtct.2024.06.013","volume":"30","author":"I Aldoss","year":"2024","unstructured":"Aldoss I, Shan H, Yang D, et al. Consolidation with first and second allogeneic transplants in adults with relapsed\/refractory B-ALL following response to CD19CAR T cell therapy. Transp Cell Thera. 2024;30:788.e781-788.e789. https:\/\/doi.org\/10.1016\/j.jtct.2024.06.013.","journal-title":"Transp Cell Thera"},{"key":"4474_CR156","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jtct.2023.10.022","volume":"30","author":"LD Anderson","year":"2024","unstructured":"Anderson LD, Dhakal B, Jain T, et al. Chimeric antigen receptor T Cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor t cells forward to earlier lines of therapy? expert panel opinion from the american society for transplantation and cellular therapy. Transp Cell Thera. 2024;30:17\u201337. https:\/\/doi.org\/10.1016\/j.jtct.2023.10.022.","journal-title":"Transp Cell Thera"},{"key":"4474_CR157","doi-asserted-by":"publisher","first-page":"290.e291","DOI":"10.1016\/j.jtct.2025.12.009","volume":"32","author":"L Karapetyan","year":"2026","unstructured":"Karapetyan L, Kuriakose J, DiMaggio E, et al. Safety and efficacy of tumor-infiltrating lymphocyte therapy with reduced-dose lymphodepleting conditioning in high-risk metastatic melanoma patients. Transp Cell Thera. 2026;32:290.e291-290.e214. https:\/\/doi.org\/10.1016\/j.jtct.2025.12.009.","journal-title":"Transp Cell Thera"},{"key":"4474_CR158","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1016\/j.ymthe.2025.03.001","volume":"33","author":"S Yang","year":"2025","unstructured":"Yang S, Wang G, Chen J, et al. Myeloma cell-intrinsic ANXA1 elevation and T cell dysfunction contribute to BCMA-negative relapse after CAR-T therapy. Mol Ther. 2025;33:3375\u201391. https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.001.","journal-title":"Mol Ther"},{"key":"4474_CR159","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.ijrobp.2025.03.023","volume":"122","author":"HS Ababneh","year":"2025","unstructured":"Ababneh HS, Ng AK, Wan J, et al. 5 5 5 ABRT (Dose of 5 Gy per fraction for up to 5 fractions over 5 weeks adaptive bridging radiation therapy)\u2014artificial intelligence enters the CAR T chimeric antigen receptor(-T) in relapsed\/refractory large B cell lymphoma. Int J Radiat Oncol Biol Phys. 2025;122:936\u201348. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.03.023.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4474_CR160","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","volume":"9","author":"R Bannerji","year":"2022","unstructured":"Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022;9:e327\u201339. https:\/\/doi.org\/10.1016\/S2352-3026(22)00072-2.","journal-title":"Lancet Haematol"},{"key":"4474_CR161","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.1182\/bloodadvances.2024013393","volume":"8","author":"GY Cederquist","year":"2024","unstructured":"Cederquist GY, Schefflein J, Devlin SM, et al. CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas. Blood Adv. 2024;8:5192\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2024013393.","journal-title":"Blood Adv"},{"key":"4474_CR162","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1182\/blood-2017-03-737460","volume":"130","author":"CK Chin","year":"2017","unstructured":"Chin CK, Cheah CY. How I treat patients with aggressive lymphoma at high risk of CNS relapse. Blood. 2017;130:867\u201374. https:\/\/doi.org\/10.1182\/blood-2017-03-737460.","journal-title":"Blood"},{"key":"4474_CR163","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD, et al. a probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37:551-568.e514. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.015.","journal-title":"Cancer Cell"},{"key":"4474_CR164","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S1470-2045(15)00584-7","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Berdeja JG, Patel MR, et al. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2016;17:622\u201331. https:\/\/doi.org\/10.1016\/S1470-2045(15)00584-7.","journal-title":"Lancet Oncol"},{"key":"4474_CR165","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.clml.2025.04.020","volume":"25","author":"SE Assouline","year":"2025","unstructured":"Assouline SE, Mehta A, Hanel W, et al. Phase I\/II Study of Subasumstat (TAK-981) in combination with rituximab in relapsed\/refractory non-hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2025;25:788-799.e711. https:\/\/doi.org\/10.1016\/j.clml.2025.04.020.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4474_CR166","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025018310","author":"RR Furman","year":"2026","unstructured":"Furman RR, Wierda WG, Patten PEM, et al. Final phase 2 study results of acalabrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia. Blood Adv. 2026. https:\/\/doi.org\/10.1182\/bloodadvances.2025018310.","journal-title":"Blood Adv"},{"key":"4474_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e35847","volume":"10","author":"M Li","year":"2024","unstructured":"Li M, Yang X, Hong Y, et al. Gilteritinib overcomes primary resistance to venetoclax in a patient with FLT3 wild-type refractory\/relapsed AML: case report and exploration of possible mechanisms. Heliyon. 2024;10:e35847. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e35847.","journal-title":"Heliyon"},{"key":"4474_CR168","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood.2023022353","volume":"145","author":"E Silkenstedt","year":"2025","unstructured":"Silkenstedt E, Dreyling M. Treatment of relapsed\/refractory MCL. Blood. 2025;145:673\u201382. https:\/\/doi.org\/10.1182\/blood.2023022353.","journal-title":"Blood"},{"key":"4474_CR169","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1182\/blood.2024026401","volume":"145","author":"W Yu","year":"2025","unstructured":"Yu W, Li P, Zhou L, et al. A phase 1 trial of prizloncabtagene autoleucel, a CD19\/CD20 CAR T-cell therapy for relapsed\/refractory B-cell non-Hodgkin lymphoma. Blood. 2025;145:1526\u201335. https:\/\/doi.org\/10.1182\/blood.2024026401.","journal-title":"Blood"},{"key":"4474_CR170","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1182\/blood.2023022241","volume":"143","author":"MH Abdelrazak Morsy","year":"2024","unstructured":"Abdelrazak Morsy MH, Lilienthal I, Lord M, et al. SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma. Blood. 2024;143:1953\u201364. https:\/\/doi.org\/10.1182\/blood.2023022241.","journal-title":"Blood"},{"key":"4474_CR171","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1182\/blood-2017-04-776740","volume":"130","author":"P Balsas","year":"2017","unstructured":"Balsas P, Palomero J, Eguileor \u00c1, et al. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. Blood. 2017;130:501\u201313. https:\/\/doi.org\/10.1182\/blood-2017-04-776740.","journal-title":"Blood"},{"key":"4474_CR172","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.ejca.2009.01.028","volume":"45","author":"DJ Brennan","year":"2009","unstructured":"Brennan DJ, Ek S, Doyle E, et al. The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer. Eur J Cancer. 2009;45:1510\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2009.01.028.","journal-title":"Eur J Cancer"},{"key":"4474_CR173","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1182\/bloodadvances.2025016801","volume":"9","author":"RP Dutta","year":"2025","unstructured":"Dutta RP, Lee H-H, Leshchenko VV, et al. SOX11 modulates BCR signaling through the PAX5\/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma. Blood Adv. 2025;9:6267\u201378. https:\/\/doi.org\/10.1182\/bloodadvances.2025016801.","journal-title":"Blood Adv"},{"key":"4474_CR174","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1182\/blood-2018-02-832535","volume":"131","author":"P-Y Kuo","year":"2018","unstructured":"Kuo P-Y, Jatiani SS, Rahman AH, et al. SOX11 augments BCR signaling to drive MCL-like tumor development. Blood. 2018;131:2247\u201355. https:\/\/doi.org\/10.1182\/blood-2018-02-832535.","journal-title":"Blood"},{"key":"4474_CR175","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.leukres.2013.07.039","volume":"37","author":"T-X Lu","year":"2013","unstructured":"Lu T-X, Li J-Y, Xu W. The role of SOX11 in mantle cell lymphoma. Leuk Res. 2013;37:1412\u20139. https:\/\/doi.org\/10.1016\/j.leukres.2013.07.039.","journal-title":"Leuk Res"},{"key":"4474_CR176","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1182\/blood-2018-05-851667","volume":"133","author":"A Mohanty","year":"2019","unstructured":"Mohanty A, Sandoval N, Phan A, et al. Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma. Blood. 2019;133:306\u201318. https:\/\/doi.org\/10.1182\/blood-2018-05-851667.","journal-title":"Blood"},{"key":"4474_CR177","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcancer.2020.06.015","volume":"67","author":"SM Tsang","year":"2020","unstructured":"Tsang SM, Oliemuller E, Howard BA. Regulatory roles for SOX11 in development, stem cells and cancer. Semin Cancer Biol. 2020;67:3\u201311. https:\/\/doi.org\/10.1016\/j.semcancer.2020.06.015.","journal-title":"Semin Cancer Biol"},{"key":"4474_CR178","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1182\/blood-2012-06-438937","volume":"121","author":"MC Vegliante","year":"2013","unstructured":"Vegliante MC, Palomero J, P\u00e9rez-Gal\u00e1n P, et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood. 2013;121:2175\u201385. https:\/\/doi.org\/10.1182\/blood-2012-06-438937.","journal-title":"Blood"},{"key":"4474_CR179","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110280","volume":"93","author":"X Xu","year":"2022","unstructured":"Xu X, Zhang T, Zhang M, et al. ATPR regulates human mantle cell lymphoma cells differentiation via SOX11\/CyclinD1\/Rb\/E2F1. Cell Signal. 2022;93:110280. https:\/\/doi.org\/10.1016\/j.cellsig.2022.110280.","journal-title":"Cell Signal"},{"key":"4474_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2025.114422","volume":"445","author":"Y Ni","year":"2025","unstructured":"Ni Y, Cao J, Li Y, Qi X. SOX11 silence inhibits atherosclerosis progression in ApoE-deficient mice by alleviating endothelial dysfunction. Exp Cell Res. 2025;445:114422. https:\/\/doi.org\/10.1016\/j.yexcr.2025.114422.","journal-title":"Exp Cell Res"},{"key":"4474_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156911","volume":"143","author":"J Lu","year":"2025","unstructured":"Lu J, Yang Y-Q, Tang J-Y, et al. CBX5 loss drives Pl3K\u03b4 inhibitor resistance in mantle cell lymphoma and propolis restores sensitivity by inducing CBX5-mediated ferroptosis. Phytomedicine. 2025;143:156911. https:\/\/doi.org\/10.1016\/j.phymed.2025.156911.","journal-title":"Phytomedicine"},{"key":"4474_CR182","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1111\/jth.15899","volume":"20","author":"CW Smith","year":"2022","unstructured":"Smith CW, Harbi MH, Garcia-Quintanilla L, et al. The Btk inhibitor AB-95-LH34 potently inhibits atherosclerotic plaque\u2013induced thrombus formation and platelet procoagulant activity. J Thromb Haemost. 2022;20:2939\u201352. https:\/\/doi.org\/10.1111\/jth.15899.","journal-title":"J Thromb Haemost"},{"key":"4474_CR183","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2026.218443","volume":"648","author":"C Yang","year":"2026","unstructured":"Yang C, Mei R, Liu J, et al. Uncontrolled hyperglycemia-induced membrane cholesterol dysregulation drives tumor immune evasion by reducing hardness of tumor cell plasma membrane. Cancer Lett. 2026;648:218443. https:\/\/doi.org\/10.1016\/j.canlet.2026.218443.","journal-title":"Cancer Lett"},{"key":"4474_CR184","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, Doorduijn J, Gin\u00e9 E, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European mantle cell lymphoma network. Lancet. 2024;403:2293\u2013306. https:\/\/doi.org\/10.1016\/S0140-6736(24)00184-3.","journal-title":"Lancet"},{"key":"4474_CR185","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jid.2022.12.008","volume":"143","author":"Y Nanri","year":"2023","unstructured":"Nanri Y, Nunomura S, Honda Y, Takedomi H, Yamaguchi Y, Izuhara K. A positive loop formed by SOX11 and periostin upregulates TGF-\u03b2 signals leading to skin fibrosis. J Investig Dermatol. 2023;143:989-998.e987. https:\/\/doi.org\/10.1016\/j.jid.2022.12.008.","journal-title":"J Investig Dermatol"},{"key":"4474_CR186","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.nbd.2015.02.025","volume":"77","author":"S Haenisch","year":"2015","unstructured":"Haenisch S, Zhao Y, Chhibber A, et al. SOX11 identified by target gene evaluation of miRNAs differentially expressed in focal and non-focal brain tissue of therapy-resistant epilepsy patients. Neurobiol Dis. 2015;77:127\u201340. https:\/\/doi.org\/10.1016\/j.nbd.2015.02.025.","journal-title":"Neurobiol Dis"},{"key":"4474_CR187","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.3324\/haematol.2024.286833","volume":"111","author":"V Ciaurro","year":"2026","unstructured":"Ciaurro V, Sharlandjieva V, Skwarska A, et al. Menin inhibitor DS-1594b drives differentiation and induces synergistic lethality in combination with venetoclax in acute myeloid leukemia cells with rearranged mixed-lineage leukemia and mutated nucleophosmin-1. Haematologica. 2026;111:1610\u201324. https:\/\/doi.org\/10.3324\/haematol.2024.286833.","journal-title":"Haematologica"},{"key":"4474_CR188","doi-asserted-by":"publisher","first-page":"168065","DOI":"10.1016\/j.bbadis.2025.168065","volume":"1872","author":"GN de Queiroz","year":"2026","unstructured":"de Queiroz GN, Lima K, Cipelli M, et al. Metabolic reprogramming represents a targetable mechanism to overcome acquired resistance to venetoclax in acute myeloid leukemia. Biochimica et Biophysica Acta (BBA)\u2014Molecular Basis of Dis. 2026;1872:168065. https:\/\/doi.org\/10.1016\/j.bbadis.2025.168065.","journal-title":"Biochimica et Biophysica Acta (BBA)\u2014Molecular Basis of Dis"},{"key":"4474_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.fmre.2026.02.010","author":"Y Deng","year":"2026","unstructured":"Deng Y, Xu C, Chu B, et al. 5-Hydroxyindirubin targets FLT3 signaling and synergizes with venetoclax in FLT3-ITD acute myeloid leukemia. Fundam Res. 2026. https:\/\/doi.org\/10.1016\/j.fmre.2026.02.010.","journal-title":"Fundam Res"},{"key":"4474_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.101036","volume":"59","author":"P Dhakal","year":"2023","unstructured":"Dhakal P, Bates M, Tomasson MH, Sutamtewagul G, Dupuy A, Bhatt VR. Acute myeloid leukemia resistant to venetoclax-based therapy: what does the future hold? Blood Rev. 2023;59:101036. https:\/\/doi.org\/10.1016\/j.blre.2022.101036.","journal-title":"Blood Rev"},{"key":"4474_CR191","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.3324\/haematol.2023.283771","volume":"109","author":"L Flanagan","year":"2024","unstructured":"Flanagan L, Coughlan A, Cosgrove N, et al. Steroid-free combination of 5-azacytidine and venetoclax for the treatment of multiple myeloma. Haematologica. 2024;109:2930\u201343. https:\/\/doi.org\/10.3324\/haematol.2023.283771.","journal-title":"Haematologica"},{"key":"4474_CR192","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2026.100591","volume":"25","author":"D Ikeda","year":"2026","unstructured":"Ikeda D, Uchiyama S, Guo Y-M, et al. FLT3 inhibitor and venetoclax therapy in elderly patients with relapsed\/refractory FLT3-ITD+ AML: A report of three cases. Leuk Res Rep. 2026;25:100591. https:\/\/doi.org\/10.1016\/j.lrr.2026.100591.","journal-title":"Leuk Res Rep"},{"key":"4474_CR193","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood.2021014241","volume":"140","author":"M Janssen","year":"2022","unstructured":"Janssen M, Schmidt C, Bruch P-M, et al. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1. Blood. 2022;140:2594\u2013610. https:\/\/doi.org\/10.1182\/blood.2021014241.","journal-title":"Blood"},{"key":"4474_CR194","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.clml.2024.01.007","volume":"24","author":"MY Konopleva","year":"2024","unstructured":"Konopleva MY, Dail M, Daver NG, et al. Venetoclax and Cobimetinib in Relapsed\/Refractory AML: A Phase 1b Trial. Clin Lymphoma Myeloma Leuk. 2024;24:364\u201374. https:\/\/doi.org\/10.1016\/j.clml.2024.01.007.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4474_CR195","doi-asserted-by":"publisher","first-page":"4058","DOI":"10.1016\/j.ymthe.2024.09.036","volume":"32","author":"Q Pan","year":"2024","unstructured":"Pan Q, Xin X, Mahto S, et al. Anti-CLL1 liposome loaded with miR-497-5p and venetoclax as a novel therapeutic strategy in acute myeloid leukemia. Mol Ther. 2024;32:4058\u201374. https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.036.","journal-title":"Mol Ther"},{"key":"4474_CR196","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1182\/bloodadvances.2022008916","volume":"7","author":"Y Sawalha","year":"2023","unstructured":"Sawalha Y, Goyal S, Switchenko JM, et al. A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma. Blood Adv. 2023;7:2983\u201393. https:\/\/doi.org\/10.1182\/bloodadvances.2022008916.","journal-title":"Blood Adv"},{"key":"4474_CR197","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.clml.2025.04.004","volume":"25","author":"C Ujjani","year":"2025","unstructured":"Ujjani C, Wang H, Broome C, et al. Ibrutinib and venetoclax in relapsed and refractory follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2025;25:739\u201345. https:\/\/doi.org\/10.1016\/j.clml.2025.04.004.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4474_CR198","doi-asserted-by":"publisher","first-page":"5806","DOI":"10.1182\/bloodadvances.2024013927","volume":"8","author":"YK Valtis","year":"2024","unstructured":"Valtis YK, Nemirovsky D, Derkach A, et al. Real-world incidence and prevention of tumor lysis syndrome in chronic lymphocytic leukemia treated with venetoclax. Blood Adv. 2024;8:5806\u201313. https:\/\/doi.org\/10.1182\/bloodadvances.2024013927.","journal-title":"Blood Adv"},{"key":"4474_CR199","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105045","volume":"217","author":"A Visentin","year":"2026","unstructured":"Visentin A, Cellini A, Angotzi F, Pepe S, Mauro FR. Venetoclax and ibrutinib: Two partners for the front-line treatment of chronic lymphocytic leukemia. Crit Rev Oncol Hematol. 2026;217:105045. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105045.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4474_CR200","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1470-2045(24)00682-X","volume":"26","author":"M Wang","year":"2025","unstructured":"Wang M, Jurczak W, Trneny M, et al. Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2025;26:200\u201313. https:\/\/doi.org\/10.1016\/S1470-2045(24)00682-X.","journal-title":"Lancet Oncol"},{"key":"4474_CR201","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2025.103864","volume":"87","author":"N Chaudhary","year":"2025","unstructured":"Chaudhary N, Mandal D, Choudhary BS, et al. Low-GPX4 drives a sustained drug-tolerant persister state in TNBC by a targetable adaptive FSP1 upregulation. Redox Biol. 2025;87:103864. https:\/\/doi.org\/10.1016\/j.redox.2025.103864.","journal-title":"Redox Biol"},{"key":"4474_CR202","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2026.107434","volume":"218","author":"M-Y Chen","year":"2026","unstructured":"Chen M-Y, Lai S-W, Cheng Y-C, et al. Targeting PPP1R15B and ATF4 axis in hepatocellular carcinoma: a novel strategy for overcoming lenvatinib-tolerant persister cells through GPX4-mediated ferroptosis induction. Eur J Pharm Sci. 2026;218:107434. https:\/\/doi.org\/10.1016\/j.ejps.2026.107434.","journal-title":"Eur J Pharm Sci"},{"key":"4474_CR203","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107163","volume":"203","author":"Y-C Chen","year":"2024","unstructured":"Chen Y-C, Gowda K, Amin S, Schell TD, Sharma AK, Robertson GP. Pharmacological agents targeting drug-tolerant persister cells in cancer. Pharmacol Res. 2024;203:107163. https:\/\/doi.org\/10.1016\/j.phrs.2024.107163.","journal-title":"Pharmacol Res"},{"key":"4474_CR204","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102274","volume":"53","author":"Y-C Cheng","year":"2025","unstructured":"Cheng Y-C, Chen M-Y, Yadav VK, et al. Targeting FABP4\/UCP2 axis to overcome cetuximab resistance in obesity-driven CRC with drug-tolerant persister cells. Trans Oncol. 2025;53:102274. https:\/\/doi.org\/10.1016\/j.tranon.2025.102274.","journal-title":"Trans Oncol"},{"key":"4474_CR205","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2026.102673","volume":"65","author":"HH Ling","year":"2026","unstructured":"Ling HH, Huang C-M, Hsieh M-S, et al. RHOJ-induced chemotherapy resistance through epithelial\u2013mesenchymal transition in drug-tolerant persister cells of head and neck cancer. Transl Oncol. 2026;65:102673. https:\/\/doi.org\/10.1016\/j.tranon.2026.102673.","journal-title":"Transl Oncol"},{"key":"4474_CR206","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102579","volume":"63","author":"HH Ling","year":"2026","unstructured":"Ling HH, Huang H-Y, Huang C-M, et al. Drug-tolerant persister cells in head and neck squamous cell carcinoma: Molecular mechanisms and therapeutic opportunities. Transl Oncol. 2026;63:102579. https:\/\/doi.org\/10.1016\/j.tranon.2025.102579.","journal-title":"Transl Oncol"},{"key":"4474_CR207","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217900","volume":"630","author":"N Yazdi","year":"2025","unstructured":"Yazdi N, Pourjamal N, Katainen R, et al. Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates. Cancer Lett. 2025;630:217900. https:\/\/doi.org\/10.1016\/j.canlet.2025.217900.","journal-title":"Cancer Lett"},{"key":"4474_CR208","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.10.001","volume":"21","author":"X Zhang","year":"2026","unstructured":"Zhang X, Wen Y, Wu F, et al. GSTA1 Conferred tolerance to osimertinib and provided strategies to overcome drug-tolerant persister in EGFR-mutant lung adenocarcinoma. J Thorac Oncol. 2026;21:103494. https:\/\/doi.org\/10.1016\/j.jtho.2025.10.001.","journal-title":"J Thorac Oncol"},{"key":"4474_CR209","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.152107","volume":"775","author":"M Zhou","year":"2025","unstructured":"Zhou M, Haga Y, Nishimura A, Tanahashi S, Higashisaka K, Tsutsumi Y. Cell cycle dynamics analysis of drug-tolerant persister cells in non-small cell lung cancer. Biochem Biophys Res Commun. 2025;775:152107. https:\/\/doi.org\/10.1016\/j.bbrc.2025.152107.","journal-title":"Biochem Biophys Res Commun"},{"key":"4474_CR210","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3324\/haematol.2025.287547","volume":"111","author":"M Alhomoud","year":"2026","unstructured":"Alhomoud M, Ibrahim R, Demetres M, et al. Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis. Haematologica. 2026;111:876\u201391. https:\/\/doi.org\/10.3324\/haematol.2025.287547.","journal-title":"Haematologica"},{"key":"4474_CR211","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1182\/bloodadvances.2024015732","volume":"9","author":"JH Frenking","year":"2025","unstructured":"Frenking JH, Zhou X, Rejeski K, et al. Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma. Blood Adv. 2025;9:4151\u201366. https:\/\/doi.org\/10.1182\/bloodadvances.2024015732.","journal-title":"Blood Adv"},{"key":"4474_CR212","doi-asserted-by":"publisher","first-page":"259.e251","DOI":"10.1016\/j.jtct.2022.12.021","volume":"29","author":"H Hubbeling","year":"2023","unstructured":"Hubbeling H, Silverman EA, Michaud L, et al. Bridging radiation rapidly and effectively cytoreduces high-risk relapsed\/refractory aggressive b cell lymphomas prior to chimeric antigen receptor T cell therapy. Transp Cell Thera. 2023;29:259.e251-259.e210. https:\/\/doi.org\/10.1016\/j.jtct.2022.12.021.","journal-title":"Transp Cell Thera"},{"key":"4474_CR213","doi-asserted-by":"publisher","first-page":"6308","DOI":"10.1182\/bloodadvances.2024012599","volume":"8","author":"N Kostopoulos","year":"2024","unstructured":"Kostopoulos N, Costabile F, Krimitza E, et al. Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration. Blood Adv. 2024;8:6308\u201320. https:\/\/doi.org\/10.1182\/bloodadvances.2024012599.","journal-title":"Blood Adv"},{"key":"4474_CR214","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.ijrobp.2024.09.023","volume":"121","author":"GS Manzar","year":"2025","unstructured":"Manzar GS, Wu SY, Dudzinski SO, et al. Characterization of lymphopenia and correlating the risk of cytopenias with dose and bone marrow volume irradiated in aggressive B cell lymphoma patients bridged with radiation therapy for chimeric antigen receptor -T cell therapy. Int J Radiat Oncol Biol Phys. 2025;121:1011\u201325. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.09.023.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4474_CR215","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108763","volume":"266","author":"K Misawa","year":"2025","unstructured":"Misawa K, Bhat H, Adusumilli PS, Hou Z. Combinational CAR T-cell therapy for solid tumors: requisites, rationales, and trials. Pharmacol Ther. 2025;266:108763. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108763.","journal-title":"Pharmacol Ther"},{"key":"4474_CR216","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.radonc.2021.11.031","volume":"166","author":"O Saifi","year":"2022","unstructured":"Saifi O, Breen WG, Lester SC, et al. Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma? Radiother Oncol. 2022;166:171\u20139. https:\/\/doi.org\/10.1016\/j.radonc.2021.11.031.","journal-title":"Radiother Oncol"},{"key":"4474_CR217","doi-asserted-by":"publisher","first-page":"13","DOI":"10.14338\/IJPT-20-00004.1","volume":"7","author":"O Saifi","year":"2020","unstructured":"Saifi O, Kharfan-Dabaja MA, Zeidan YH, et al. Proton Therapy as a Bridging Treatment in CAR T- Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma Is There a Role? Int J Part Thera. 2020;7:13\u201320. https:\/\/doi.org\/10.14338\/IJPT-20-00004.1.","journal-title":"Int J Part Thera"},{"key":"4474_CR218","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.semradonc.2024.10.005","volume":"35","author":"DG Wallington","year":"2025","unstructured":"Wallington DG, Imber BS, Scordo M, Robinson TJ. The role of radiotherapy in lymphoma patients undergoing CAR T therapy: past, present, and future. Seminars Radiat Oncol. 2025;35:99\u2013109. https:\/\/doi.org\/10.1016\/j.semradonc.2024.10.005.","journal-title":"Seminars Radiat Oncol"},{"key":"4474_CR219","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.ymthe.2025.12.068","volume":"34","author":"Z Yao","year":"2026","unstructured":"Yao Z, Kang K, Li P-H, et al. Dual-targeting CD133\/PD-L1 CAR-T plus \u03b1PD-1 overcomes immunosuppressive microenvironment and enhanced by radiation pre-conditioning. Mol Ther. 2026;34:1483\u2013502. https:\/\/doi.org\/10.1016\/j.ymthe.2025.12.068.","journal-title":"Mol Ther"},{"key":"4474_CR220","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104390","volume":"199","author":"L Yu","year":"2024","unstructured":"Yu L, Zou R, He J, Qu C. Role of radiation in chimeric antigen receptor T-cell therapy for patients with relapsed\/refractory non-Hodgkin lymphoma: current studies and future prospects. Crit Rev Oncol Hematol. 2024;199:104390. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104390.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4474_CR221","doi-asserted-by":"publisher","DOI":"10.1016\/j.tru.2024.100186","volume":"16","author":"P Evangelidis","year":"2024","unstructured":"Evangelidis P, Gavriilaki E, Tsakiris DA. Thrombotic complications after hematopoietic stem cell transplantation and other cellular therapies. Thrombosis Update. 2024;16:100186. https:\/\/doi.org\/10.1016\/j.tru.2024.100186.","journal-title":"Thrombosis Update"},{"key":"4474_CR222","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2026.02.002","author":"D Kishi","year":"2026","unstructured":"Kishi D, Shimomura Y, Yamashita D, et al. Clinical characteristics and treatment outcomes of autoimmune-like hepatitis after allogeneic hematopoietic stem cell transplantation. Transpl Cell Thera. 2026. https:\/\/doi.org\/10.1016\/j.jtct.2026.02.002.","journal-title":"Transpl Cell Thera"},{"key":"4474_CR223","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2026.03.010","author":"JE Maakaron","year":"2026","unstructured":"Maakaron JE, Zhao Q, Balakrishna JP, et al. Phase I trial of venetoclax and beam followed by autologous stem cell transplant for high-risk non-Hodgkin lymphoma. Transpl and Cell Thera. 2026. https:\/\/doi.org\/10.1016\/j.jtct.2026.03.010.","journal-title":"Transpl and Cell Thera"},{"key":"4474_CR224","doi-asserted-by":"publisher","first-page":"1206.e1201","DOI":"10.1016\/j.jtct.2024.09.023","volume":"30","author":"A Merino","year":"2024","unstructured":"Merino A, Brunstein CC, Shanley R, et al. N-803, an IL-15 superagonist complex as maintenance therapy after allogeneic donor stem cell transplant for acute myeloid leukemia or myelodysplastic syndrome; a Phase 2 trial. Transpl Cell Thera. 2024;30:1206.e1201-1206.e1212. https:\/\/doi.org\/10.1016\/j.jtct.2024.09.023.","journal-title":"Transpl Cell Thera"},{"key":"4474_CR225","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.molmed.2023.05.008","volume":"29","author":"A Nash","year":"2023","unstructured":"Nash A, Lokhorst N, Veiseh O. Localized immunomodulation technologies to enable cellular and organoid transplantation. Trends Mol Med. 2023;29:635\u201345. https:\/\/doi.org\/10.1016\/j.molmed.2023.05.008.","journal-title":"Trends Mol Med"},{"key":"4474_CR226","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100883","volume":"51","author":"N Sumransub","year":"2022","unstructured":"Sumransub N, El Jurdi N, Chiraphapphaiboon W, Maakaron JE. Putting function back in dysfunction: endothelial diseases and current therapies in hematopoietic stem cell transplantation and cellular therapies. Blood Rev. 2022;51:100883. https:\/\/doi.org\/10.1016\/j.blre.2021.100883.","journal-title":"Blood Rev"},{"key":"4474_CR227","doi-asserted-by":"publisher","first-page":"806.e801","DOI":"10.1016\/j.jtct.2025.06.004","volume":"31","author":"C Tarella","year":"2025","unstructured":"Tarella C, Sammassimo S, Frassoni S, et al. Long-term outcomes after allogeneic hematopoietic stem cell transplantation in relapsed\/refractory b-cell non-hodgkin lymphoma: an italian multicenter collaborative study. Transpl Cell Thera. 2025;31:806.e801-806.e819. https:\/\/doi.org\/10.1016\/j.jtct.2025.06.004.","journal-title":"Transpl Cell Thera"},{"key":"4474_CR228","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102594","volume":"63","author":"H Tian","year":"2026","unstructured":"Tian H, Wang R, Cong D, Bai Y, Zhang W. Evolution of conditioning regimens prior to autologous stem cell transplantation in lymphoma patients. Transl Oncol. 2026;63:102594. https:\/\/doi.org\/10.1016\/j.tranon.2025.102594.","journal-title":"Transl Oncol"},{"key":"4474_CR229","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.11.020","author":"A von Werdt","year":"2025","unstructured":"von Werdt A, K\u00fcnzi A, Haynes A, et al. Late toxicity of allogeneic stem cell transplantation for Non-Hodgkin lymphoma patients SBST based analysis 1997\u20132021 and review of literature. Transp Cell Thera. 2025. https:\/\/doi.org\/10.1016\/j.jtct.2025.11.020.","journal-title":"Transp Cell Thera"},{"key":"4474_CR230","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jcyt.2024.01.012","volume":"26","author":"X Xin","year":"2024","unstructured":"Xin X, Lin L, Yang Y, et al. Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory\/relapsed B-cell non-Hodgkin-lymphoma. Cytotherapy. 2024;26:456\u201365. https:\/\/doi.org\/10.1016\/j.jcyt.2024.01.012.","journal-title":"Cytotherapy"},{"key":"4474_CR231","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1182\/blood.2021011787","volume":"138","author":"M Butler","year":"2021","unstructured":"Butler M, van Ingen Schenau DS, Yu J, et al. BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway. Blood. 2021;138:2383\u201395. https:\/\/doi.org\/10.1182\/blood.2021011787.","journal-title":"Blood"},{"key":"4474_CR232","doi-asserted-by":"publisher","DOI":"10.1016\/j.slast.2025.100307","volume":"33","author":"R Cheng","year":"2025","unstructured":"Cheng R, Muneer A, Hercher M, Bajrami B, Nemati R. Acoustic ejection mass spectrometry: an integrated pipeline for ultra-high throughput screening, reactivity profiling, and potency analysis of covalent BTK inhibitors. SLAS Technol. 2025;33:100307. https:\/\/doi.org\/10.1016\/j.slast.2025.100307.","journal-title":"SLAS Technol"},{"key":"4474_CR233","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3324\/haematol.2024.286205","volume":"110","author":"BT Grainger","year":"2025","unstructured":"Grainger BT, Cheah CY. \u201cThe End of the Golden Weather\u201d: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors. Haematologica. 2025;110:576\u201387. https:\/\/doi.org\/10.3324\/haematol.2024.286205.","journal-title":"Haematologica"},{"key":"4474_CR234","doi-asserted-by":"publisher","DOI":"10.1016\/j.jscai.2025.104107","volume":"5","author":"J-K Lee","year":"2026","unstructured":"Lee J-K, Pin R, Jansen S, et al. Pharmacokinetic profile of everolimus eluted from the esprit BTK scaffold: a Life-BTK pharmacokinetics substudy. J Soc Cardiovasc Angiogr Interv. 2026;5:104107. https:\/\/doi.org\/10.1016\/j.jscai.2025.104107.","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"key":"4474_CR235","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113329","volume":"217","author":"J Liu","year":"2021","unstructured":"Liu J, Chen C, Wang D, Zhang J, Zhang T. Emerging small-molecule inhibitors of the Bruton\u2019s tyrosine kinase (BTK): current development. Eur J Med Chem. 2021;217:113329. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113329.","journal-title":"Eur J Med Chem"},{"key":"4474_CR236","doi-asserted-by":"publisher","first-page":"16242","DOI":"10.1021\/acs.jmedchem.1c01559","volume":"64","author":"C Ma","year":"2021","unstructured":"Ma C, Li Q, Zhao M, et al. Discovery of 1-Amino-1H-imidazole-5-carboxamide derivatives as highly selective, covalent bruton\u2019s tyrosine kinase (BTK) inhibitors. J Med Chem. 2021;64:16242\u201370. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01559.","journal-title":"J Med Chem"},{"key":"4474_CR237","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.114009","volume":"229","author":"F Ran","year":"2022","unstructured":"Ran F, Liu Y, Wang C, et al. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. Eur J Med Chem. 2022;229:114009. https:\/\/doi.org\/10.1016\/j.ejmech.2021.114009.","journal-title":"Eur J Med Chem"},{"key":"4474_CR238","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114232","volume":"233","author":"F Ran","year":"2022","unstructured":"Ran F, Liu Y, Xu Z, et al. Recent development of BTK-based dual inhibitors in the treatment of cancers. Eur J Med Chem. 2022;233:114232. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114232.","journal-title":"Eur J Med Chem"},{"key":"4474_CR239","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107615","volume":"147","author":"J Shen","year":"2024","unstructured":"Shen J, Li J, Yang R, et al. Advances in the treatment of mantle cell lymphoma with BTK inhibitors. Leuk Res. 2024;147:107615. https:\/\/doi.org\/10.1016\/j.leukres.2024.107615.","journal-title":"Leuk Res"},{"key":"4474_CR240","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1182\/blood.2023020240","volume":"141","author":"PA Thompson","year":"2023","unstructured":"Thompson PA, Tam CS. Pirtobrutinib: a new hope for patients with BTK inhibitor\u2013refractory lymphoproliferative disorders. Blood. 2023;141:3137\u201342. https:\/\/doi.org\/10.1182\/blood.2023020240.","journal-title":"Blood"},{"key":"4474_CR241","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106577","volume":"138","author":"L Wang","year":"2023","unstructured":"Wang L, Zhang Z, Yu D, et al. Recent research of BTK inhibitors: Methods of structural design, pharmacological activities, manmade derivatives and structure\u2013activity relationship. Bioorg Chem. 2023;138:106577. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106577.","journal-title":"Bioorg Chem"},{"key":"4474_CR242","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2025.117867","volume":"289","author":"X Zhao","year":"2025","unstructured":"Zhao X, Gu Y, Xie Y, et al. A BTK-activatable targeted covalent NIR fluorescent probe for kinase monitoring and B-cell lymphoma imaging. Biosens Bioelectron. 2025;289:117867. https:\/\/doi.org\/10.1016\/j.bios.2025.117867.","journal-title":"Biosens Bioelectron"},{"key":"4474_CR243","doi-asserted-by":"publisher","first-page":"35336","DOI":"10.1039\/d5ra04840k","volume":"15","author":"L-T Zheng","year":"2025","unstructured":"Zheng L-T, Qian K, Zhang J, Liu M-T, Li Y, Yang L-Q. Exploring pocket-aware inhibitors of BTK kinase by generative deep learning, molecular docking, and molecular dynamics simulations. RSC Adv. 2025;15:35336\u201355. https:\/\/doi.org\/10.1039\/d5ra04840k.","journal-title":"RSC Adv"},{"key":"4474_CR244","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1182\/bloodadvances.2024013747","volume":"8","author":"I Aldoss","year":"2024","unstructured":"Aldoss I, Roloff GW, Faramand R, et al. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. Blood Adv. 2024;8:6139\u201347. https:\/\/doi.org\/10.1182\/bloodadvances.2024013747.","journal-title":"Blood Adv"},{"key":"4474_CR245","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104969","volume":"216","author":"Z Chen","year":"2025","unstructured":"Chen Z, Luo W, Kang Y, et al. Comparison of regional differences in safety and efficacy of CAR-T therapy for hematologic malignancies in a real-world setting: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2025;216:104969. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104969.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4474_CR246","doi-asserted-by":"publisher","DOI":"10.1016\/j.bict.2026.100059","author":"N Jain","year":"2026","unstructured":"Jain N, Khaire N, Short N, et al. Brexucabtagene autoleucel consolidation in adult B-cell acute lymphoblastic leukemia: real-world efficacy and toxicity. Blood Immunol Cell Thera. 2026. https:\/\/doi.org\/10.1016\/j.bict.2026.100059.","journal-title":"Blood Immunol Cell Thera"},{"key":"4474_CR247","doi-asserted-by":"publisher","first-page":"5249","DOI":"10.1182\/bloodadvances.2025015881","volume":"9","author":"S John","year":"2025","unstructured":"John S, Curran KJ, Hall EM, et al. Real-world data for tisagenlecleucel in patients with R\/R B-ALL: subgroup analyses from the CIBMTR registry. Blood Adv. 2025;9:5249\u201362. https:\/\/doi.org\/10.1182\/bloodadvances.2025015881.","journal-title":"Blood Adv"},{"key":"4474_CR248","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2026.04.019","author":"S Koeck","year":"2026","unstructured":"Koeck S, Rotter N, Stiefel O, et al. Austrian real-world experience with standard of care brexucabtagene autoleucel in patients with relapsed or refractory mantle-cell lymphoma. Transpl Cell Thera. 2026. https:\/\/doi.org\/10.1016\/j.jtct.2026.04.019.","journal-title":"Transpl Cell Thera"},{"key":"4474_CR249","doi-asserted-by":"publisher","DOI":"10.1016\/j.bict.2025.100028","volume":"2","author":"NE Kopmar","year":"2026","unstructured":"Kopmar NE, Gooley TA, Roloff GW, et al. Real-world toxicity of brexucabtagene autoleucel in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia. Blood Immunol Cell Thera. 2026;2:100028. https:\/\/doi.org\/10.1016\/j.bict.2025.100028.","journal-title":"Blood Immunol Cell Thera"},{"key":"4474_CR250","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1182\/bloodadvances.2024014846","volume":"9","author":"H Lust","year":"2025","unstructured":"Lust H, Schultz LM, Kwon S, et al. Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy. Blood Adv. 2025;9:2763\u201372. https:\/\/doi.org\/10.1182\/bloodadvances.2024014846.","journal-title":"Blood Adv"},{"key":"4474_CR251","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1182\/bloodadvances.2024015779","volume":"9","author":"IN Muhsen","year":"2025","unstructured":"Muhsen IN, Roloff GW, Faramand R, et al. Outcomes of brexucabtagene autoleucel in patients with relapsed\/refractory acute lymphoblastic leukemia with CNS involvement. Blood Adv. 2025;9:4081\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2024015779.","journal-title":"Blood Adv"},{"key":"4474_CR252","doi-asserted-by":"publisher","DOI":"10.1016\/j.bict.2025.100026","volume":"2","author":"A Purwar","year":"2026","unstructured":"Purwar A, Jain H, Kumar S. Broadening CAR-T access: lessons from real-world implementation of talicabtagene autoleucel in India. Blood Immunol Cell Thera. 2026;2:100026. https:\/\/doi.org\/10.1016\/j.bict.2025.100026.","journal-title":"Blood Immunol Cell Thera"},{"key":"4474_CR253","doi-asserted-by":"publisher","DOI":"10.1016\/j.omta.2026.201686","volume":"34","author":"SS Salunkhe","year":"2026","unstructured":"Salunkhe SS, Nater J, Schweitzer C, et al. Comparative pharmacokinetic derivations for axicabtagene ciloleucel and brexucabtagene autoleucel in the treatment of B cell malignancies. Mol Thera Adv. 2026;34:201686. https:\/\/doi.org\/10.1016\/j.omta.2026.201686.","journal-title":"Mol Thera Adv"},{"key":"4474_CR254","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1182\/blood.2025029734","volume":"147","author":"T van Meerten","year":"2026","unstructured":"van Meerten T, Kersten MJ, Iacoboni G, et al. Brexucabtagene autoleucel for BTKi-naive relapsed\/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3. Blood. 2026;147:1302\u201314. https:\/\/doi.org\/10.1182\/blood.2025029734.","journal-title":"Blood"},{"key":"4474_CR255","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2026.03.014","author":"C Zha","year":"2026","unstructured":"Zha C, Yang Z, Li L, et al. Infections post-CAR-T therapy: a real-world pharmacovigilance analysis of the fda adverse event reporting system (FAERS) database. Clin Ther. 2026. https:\/\/doi.org\/10.1016\/j.clinthera.2026.03.014.","journal-title":"Clin Ther"},{"key":"4474_CR256","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jval.2024.09.007","volume":"28","author":"J Zong","year":"2025","unstructured":"Zong J, Rojubally A, Pan X, et al. A review and comparative case study analysis of real-world evidence in European regulatory and health technology assessment decision making for oncology medicines. Value Health. 2025;28:31\u201341. https:\/\/doi.org\/10.1016\/j.jval.2024.09.007.","journal-title":"Value Health"},{"key":"4474_CR257","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2026.124434","volume":"397","author":"A Vikal","year":"2026","unstructured":"Vikal A, Maurya R, Kumar P, Verma N, Mishra AK. Next-generation gene editing strategies in cancer: integrating CRISPR, PROTACs, and advanced molecular technologies. Life Sci. 2026;397:124434. https:\/\/doi.org\/10.1016\/j.lfs.2026.124434.","journal-title":"Life Sci"},{"key":"4474_CR258","doi-asserted-by":"publisher","unstructured":"Rodrigues DA, Pires GS, Roy U, Conway E, de Sena Murteira Pinheiro P. 2026 Fulfilling multiple roles in PROTAC design: The emerging potential of oligonucleotides. European Journal of Medicinal Chemistry. 307:118688. https:\/\/doi.org\/10.1016\/j.ejmech.2026.118688","DOI":"10.1016\/j.ejmech.2026.118688"},{"key":"4474_CR259","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2026.110045","volume":"179","author":"F Liu","year":"2026","unstructured":"Liu F, Zhang Y, Xu Y, Wu X. PROTAC technology: clinical applications, future challenges, and innovative strategies. Bioorg Chem. 2026;179:110045. https:\/\/doi.org\/10.1016\/j.bioorg.2026.110045.","journal-title":"Bioorg Chem"},{"key":"4474_CR260","doi-asserted-by":"publisher","DOI":"10.34133\/jbioxresearch.0080","author":"R Jeyavelkumaran","year":"2026","unstructured":"Jeyavelkumaran R, Bantaram J, Valliappan S, Dayalan M. Targeted protein degradation in acute myeloid leukemia emerging role of PROTACs in hematologic malignancies. J Bio-X Res. 2026. https:\/\/doi.org\/10.34133\/jbioxresearch.0080.","journal-title":"J Bio-X Res"},{"key":"4474_CR261","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2026.103234","volume":"24","author":"Z Zhou","year":"2026","unstructured":"Zhou Z, Liu P, Li Y, Liu X, Li J. Opportunities and challenges of PROTAC in the treatment of protein-driven diseases. Res Chem. 2026;24:103234. https:\/\/doi.org\/10.1016\/j.rechem.2026.103234.","journal-title":"Res Chem"},{"key":"4474_CR262","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2026.115086","author":"Y Lin","year":"2026","unstructured":"Lin Y, Huang J, Huang Z, et al. Ultrasound-activated biomimetic nanobubbles achieve synergistic immunotherapy by tumor cell membrane-based vaccination and PD-L1 PROTAC degradation. J Controlled Releas. 2026. https:\/\/doi.org\/10.1016\/j.jconrel.2026.115086.","journal-title":"J Controlled Releas"},{"key":"4474_CR263","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101316","volume":"84","author":"L Zhang","year":"2026","unstructured":"Zhang L, He L, Lin Y, et al. The novel strategy to overcome the drug-resistant lung cancer: dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells. Drug Resist Updates. 2026;84:101316. https:\/\/doi.org\/10.1016\/j.drup.2025.101316.","journal-title":"Drug Resist Updates"},{"key":"4474_CR264","doi-asserted-by":"publisher","first-page":"e699","DOI":"10.1016\/j.clml.2026.03.003","volume":"26","author":"L Cani","year":"2026","unstructured":"Cani L, Parikh R, Joseph NS, et al. The evolution of chimeric antigen receptor T-Cell, bispecific antibodies and antibody-drug conjugates for the treatment of multiple myeloma. Clin Lymphoma Myeloma Leuk. 2026;26:e699\u2013714. https:\/\/doi.org\/10.1016\/j.clml.2026.03.003.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4474_CR265","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.amjms.2025.10.007","volume":"371","author":"B Dye","year":"2026","unstructured":"Dye B, Gromer D, Maryam B, Siegrist EA, Sassine J. Infectious complications of chimeric antigen receptor T cell therapy and bispecific antibodies \u2013 A review. Am J Med Sci. 2026;371:170\u20138. https:\/\/doi.org\/10.1016\/j.amjms.2025.10.007.","journal-title":"Am J Med Sci"},{"key":"4474_CR266","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105003","volume":"216","author":"AS Fattahi","year":"2025","unstructured":"Fattahi AS, Haghighi E. Beyond monospecificity: The modular revolution of bispecific immunotherapeutics. Crit Rev Oncol Hematol. 2025;216:105003. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105003.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4474_CR267","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104752","volume":"212","author":"L Han","year":"2025","unstructured":"Han L, Wang K, Jiang Z, Guo X, Yu J. Recent development in bispecific antibody immunotherapy for hematological malignancies. Crit Rev Oncol Hematol. 2025;212:104752. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104752.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4474_CR268","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115597","volume":"166","author":"MC Jamali","year":"2025","unstructured":"Jamali MC, Gaffer AGM, Hassan HG, et al. Engineering scFv immunotherapies: From CAR T cells to bispecific antibodies. Int Immunopharmacol. 2025;166:115597. https:\/\/doi.org\/10.1016\/j.intimp.2025.115597.","journal-title":"Int Immunopharmacol"},{"key":"4474_CR269","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpccr.2026.100414","volume":"21","author":"S Jung","year":"2026","unstructured":"Jung S, Gates K, Collins HH, et al. Durable response to bispecific PD-1\/ICOS antibody and ipilimumab in advanced microsatellite-stable colorectal cancer: a case report. Curr Probl Cancer: Case Rep. 2026;21:100414. https:\/\/doi.org\/10.1016\/j.cpccr.2026.100414.","journal-title":"Curr Probl Cancer: Case Rep"},{"key":"4474_CR270","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.seminhematol.2025.11.002","volume":"62","author":"K-N Koh","year":"2025","unstructured":"Koh K-N, Kim DH, Kim H. Trispecific T cell engagers in hematological malignancies: Advancing beyond bispecific antibodies. Semin Hematol. 2025;62:350\u20136. https:\/\/doi.org\/10.1053\/j.seminhematol.2025.11.002.","journal-title":"Semin Hematol"},{"key":"4474_CR271","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1053\/j.seminhematol.2025.08.004","volume":"62","author":"H Lee","year":"2025","unstructured":"Lee H, Lee Y, Chung J. Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers. Semin Hematol. 2025;62:279\u201388. https:\/\/doi.org\/10.1053\/j.seminhematol.2025.08.004.","journal-title":"Semin Hematol"},{"key":"4474_CR272","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.molimm.2023.08.007","volume":"162","author":"Q Liu","year":"2023","unstructured":"Liu Q, Song Q, Luo C, et al. A novel bispecific antibody as an immunotherapeutic agent in hepatocellular carcinoma. Mol Immunol. 2023;162:125\u201332. https:\/\/doi.org\/10.1016\/j.molimm.2023.08.007.","journal-title":"Mol Immunol"},{"key":"4474_CR273","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpet.2025.103704","volume":"392","author":"T Nahle","year":"2025","unstructured":"Nahle T, Shah V, Farraj SA, Atoui A. Next-generation T cell engagers in oncology: Pharmacologic evolution from bispecific to trispecific antibodies. J Pharmacol Exp Ther. 2025;392:103704. https:\/\/doi.org\/10.1016\/j.jpet.2025.103704.","journal-title":"J Pharmacol Exp Ther"},{"key":"4474_CR274","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2026.116747","volume":"181","author":"A Pandey","year":"2026","unstructured":"Pandey A, Wankhade S, Murthy A, et al. The rise of bispecific antibodies for dual targeting, singular impact: technology and clinical advancements. Int Immunopharmacol. 2026;181:116747. https:\/\/doi.org\/10.1016\/j.intimp.2026.116747.","journal-title":"Int Immunopharmacol"},{"key":"4474_CR275","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2026.119020","volume":"196","author":"M Shokouhfar","year":"2026","unstructured":"Shokouhfar M, Darzi A, Ameli F, et al. Immunotherapeutic advances in pediatric neuroblastoma: Overcoming resistance through biomarker-guided combinations. Biomed Pharmacother. 2026;196:119020. https:\/\/doi.org\/10.1016\/j.biopha.2026.119020.","journal-title":"Biomed Pharmacother"},{"key":"4474_CR276","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2026.151878","volume":"360","author":"R Yuan","year":"2026","unstructured":"Yuan R, Zhang Y, Liu S, et al. A rationally designed bispecific antibody targeting GPC3 and PD-L1 induces tumor-directed immune activation and cytotoxicity. Int J Biol Macromol. 2026;360:151878. https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.151878.","journal-title":"Int J Biol Macromol"},{"key":"4474_CR277","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2026.103502","volume":"101","author":"Y Zhao","year":"2026","unstructured":"Zhao Y, Sun Y, Sun H, et al. Treatment of acute myeloid leukemia using CD3\/CD123 bispecific antibody-engaged \u03b3\u03b4T cells in a mouse xenograft model. Tissue Cell. 2026;101:103502. https:\/\/doi.org\/10.1016\/j.tice.2026.103502.","journal-title":"Tissue Cell"},{"key":"4474_CR278","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101342","volume":"74","author":"X Zhou","year":"2025","unstructured":"Zhou X, Waldschmidt JM, Einsele H. Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies. Blood Rev. 2025;74:101342. https:\/\/doi.org\/10.1016\/j.blre.2025.101342.","journal-title":"Blood Rev"},{"key":"4474_CR279","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1182\/bloodadvances.2022008802","volume":"7","author":"GAA Burke","year":"2023","unstructured":"Burke GAA, Vinti L, Kabickova E, et al. Ibrutinib plus RICE or RVICI for relapsed\/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial. Blood Adv. 2023;7:602\u201310. https:\/\/doi.org\/10.1182\/bloodadvances.2022008802.","journal-title":"Blood Adv"},{"key":"4474_CR280","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2026.04.025","author":"JB Cohen","year":"2026","unstructured":"Cohen JB, Portell CA, Hamadani M, et al. An Evaluation of Ibrutinib and Ixazomib in Patients with Relapsed\/Refractory Mantle Cell Lymphoma: PrE0404. Clin Lymphoma Myeloma Leuk. 2026. https:\/\/doi.org\/10.1016\/j.clml.2026.04.025.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4474_CR281","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1182\/bloodadvances.2025018137","volume":"10","author":"EP Darnell","year":"2026","unstructured":"Darnell EP, Gallagher KME, Kanska J, et al. Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma. Blood Adv. 2026;10:1023\u201334. https:\/\/doi.org\/10.1182\/bloodadvances.2025018137.","journal-title":"Blood Adv"},{"key":"4474_CR282","doi-asserted-by":"publisher","first-page":"4849","DOI":"10.1182\/bloodadvances.2020002810","volume":"4","author":"JE Davis","year":"2020","unstructured":"Davis JE, Handunnetti SM, Ludford-Menting M, et al. Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. Blood Adv. 2020;4:4849\u201359. https:\/\/doi.org\/10.1182\/bloodadvances.2020002810.","journal-title":"Blood Adv"},{"key":"4474_CR283","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101082","volume":"74","author":"Y Huang","year":"2024","unstructured":"Huang Y, Qin Y, He Y, et al. Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies. Drug Resist Updates. 2024;74:101082. https:\/\/doi.org\/10.1016\/j.drup.2024.101082.","journal-title":"Drug Resist Updates"},{"key":"4474_CR284","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2026.101269","volume":"61","author":"S Vaja","year":"2026","unstructured":"Vaja S, Khandelwal S, Vora C, et al. CAR-T\/NK\/M-based combination therapies in cancer: a comprehensive review. Curr Probl Cancer. 2026;61:101269. https:\/\/doi.org\/10.1016\/j.currproblcancer.2026.101269.","journal-title":"Curr Probl Cancer"},{"key":"4474_CR285","doi-asserted-by":"publisher","DOI":"10.1016\/j.bict.2025.100030","volume":"2","author":"M Drayton","year":"2026","unstructured":"Drayton M, Kuchenbauer F, Cherniawsky H. CAR-NK cell therapy in acute myeloid leukemia: safer, smarter, and moving toward clinical translation. Blood Immunol Cell Thera. 2026;2:100030. https:\/\/doi.org\/10.1016\/j.bict.2025.100030.","journal-title":"Blood Immunol Cell Thera"},{"key":"4474_CR286","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ymthe.2025.12.005","volume":"34","author":"A Fiori","year":"2026","unstructured":"Fiori A, Zimmermann K, Li A, et al. Bispecific BAFF-R\/BCMA CAR T cells control growth of heterogeneous plasma cells in multiple myeloma. Mol Ther. 2026;34:1399\u2013420. https:\/\/doi.org\/10.1016\/j.ymthe.2025.12.005.","journal-title":"Mol Ther"},{"key":"4474_CR287","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2026.03.047","author":"L Gattinoni","year":"2026","unstructured":"Gattinoni L, Inchingolo G, Harrer DC, et al. Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse. Cell. 2026. https:\/\/doi.org\/10.1016\/j.cell.2026.03.047.","journal-title":"Cell"},{"key":"4474_CR288","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.semcancer.2026.02.001","volume":"120","author":"TGP Gr\u00fcnewald","year":"2026","unstructured":"Gr\u00fcnewald TGP, Oehme I, Wagner J, Fr\u00f6hling S. Intratumor heterogeneity and clonal evolution in sarcomas: Molecular, cellular, and functional drivers of therapy resistance. Semin Cancer Biol. 2026;120:31\u201347. https:\/\/doi.org\/10.1016\/j.semcancer.2026.02.001.","journal-title":"Semin Cancer Biol"},{"key":"4474_CR289","doi-asserted-by":"publisher","first-page":"103164","DOI":"10.1016\/j.tice.2025.103164","volume":"98","author":"M Mahmoudi","year":"2026","unstructured":"Mahmoudi M, Agah SA, et al. CAR T cell therapy in autoimmune diseases Opportunities and challenges with implications for RA. Tissue Cell. 2026;98:103164. https:\/\/doi.org\/10.1016\/j.tice.2025.103164.","journal-title":"Tissue Cell"},{"key":"4474_CR290","doi-asserted-by":"publisher","first-page":"114607","DOI":"10.1016\/j.isci.2025.114607","volume":"29","author":"X Li","year":"2026","unstructured":"Li X, Wang Z, Mao S, et al. Integrating CAR-T therapy with PD-1\/PD-L1 blockade mechanisms, synergy, and optimized strategies in NSCLC. iScience. 2026;29:114607. https:\/\/doi.org\/10.1016\/j.isci.2025.114607.","journal-title":"iScience"},{"key":"4474_CR291","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2026.02.008","author":"C\u00d8 Madsen","year":"2026","unstructured":"Madsen C\u00d8, Hulen TM, Ormh\u00f8j M, Hadrup SR, Svane IM, Met \u00d6. Driving CAR therapies beyond T cells. Trends Cancer. 2026. https:\/\/doi.org\/10.1016\/j.trecan.2026.02.008.","journal-title":"Trends Cancer"},{"key":"4474_CR292","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2026.101028","volume":"7","author":"R Rosa","year":"2026","unstructured":"Rosa R, Liu J, Lu C, Abou-el-Enein M, Murad JP, Priceman SJ. Current state of CAR-T cell therapies for solid tumors. Med. 2026;7:101028. https:\/\/doi.org\/10.1016\/j.medj.2026.101028.","journal-title":"Med"},{"key":"4474_CR293","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2026.118827","volume":"200","author":"T Wu","year":"2026","unstructured":"Wu T, Wu D, Zeng H. Insights into the efficacy and safety of CAR-T therapies using organoids and organs-on-chips. TrAC, Trends Anal Chem. 2026;200:118827. https:\/\/doi.org\/10.1016\/j.trac.2026.118827.","journal-title":"TrAC, Trends Anal Chem"},{"key":"4474_CR294","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025019510","author":"Y Yagi","year":"2026","unstructured":"Yagi Y, Kanemasa Y, Terao T, et al. Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese Nationwide registry analysis. Blood Adv. 2026. https:\/\/doi.org\/10.1182\/bloodadvances.2025019510.","journal-title":"Blood Adv"},{"key":"4474_CR295","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2026.03.002","author":"Z Zhang","year":"2026","unstructured":"Zhang Z, Ho Y-J, Fang X, et al. A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. Cell. 2026. https:\/\/doi.org\/10.1016\/j.cell.2026.03.002.","journal-title":"Cell"},{"key":"4474_CR296","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2025.217388","volume":"550","author":"M Zuo","year":"2026","unstructured":"Zuo M, Wang J, Zhang W, et al. Nano-\/nanobio-technology-enhanced CAR-T cell therapy: engineering the next generation of immunotherapies. Coord Chem Rev. 2026;550:217388. https:\/\/doi.org\/10.1016\/j.ccr.2025.217388.","journal-title":"Coord Chem Rev"},{"key":"4474_CR297","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104239","volume":"29","author":"SM Bates","year":"2024","unstructured":"Bates SM, Evans KV, Delsing L, Wong R, Cornish G, Bahjat M. Immune safety challenges facing the preclinical assessment and clinical progression of cell therapies. Drug Discov Today. 2024;29:104239. https:\/\/doi.org\/10.1016\/j.drudis.2024.104239.","journal-title":"Drug Discov Today"},{"key":"4474_CR298","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2026.114839","volume":"394","author":"J Cordeiro","year":"2026","unstructured":"Cordeiro J, Macela C, Kleiner R, et al. Harnessing the power of microbiome, nanotechnology, and immunity against cancer. J Control Rel. 2026;394:114839. https:\/\/doi.org\/10.1016\/j.jconrel.2026.114839.","journal-title":"J Control Rel"},{"key":"4474_CR299","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2026.02.013","author":"E Dehdashtian","year":"2026","unstructured":"Dehdashtian E, Hu G, Whiteman L, et al. Neutrophil transcriptomics in SLE reveals intrinsic disease signatures, shared ex vivo adaptation, and transcriptional reset after CAR T-cell therapy. Ann Rheum Dis. 2026. https:\/\/doi.org\/10.1016\/j.ard.2026.02.013.","journal-title":"Ann Rheum Dis"},{"key":"4474_CR300","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2026.104254","volume":"115","author":"I Gopallawa","year":"2026","unstructured":"Gopallawa I, Chavan S, Goswami A, Jawa V, Chirmule N. A quantitative metric of immune responses with applications in vaccines, cancer immunity, autoimmunity, and anti-drug antibody monitoring. J Pharm Sci. 2026;115:104254. https:\/\/doi.org\/10.1016\/j.xphs.2026.104254.","journal-title":"J Pharm Sci"},{"key":"4474_CR301","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189504","volume":"1881","author":"R Gupta","year":"2026","unstructured":"Gupta R, Radhakrishnan R, Kabekkodu SP, Chakrabarty S. Application of in vitro and in vivo cancer models to study the impact of the tumor immune microenvironment on anticancer therapy. Biochimica et Biophysica Acta (BBA) Rev Cancer. 2026;1881:189504. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189504.","journal-title":"Biochimica et Biophysica Acta (BBA) Rev Cancer."},{"key":"4474_CR302","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114837","volume":"159","author":"R Keshavarz Sadegh","year":"2025","unstructured":"Keshavarz Sadegh R, Saleki K, Rezaei N. Immune checkpoint inhibitor (ICI) therapy in central nervous system cancers: state-of-the-art and future outlook. Int Immunopharmacol. 2025;159:114837. https:\/\/doi.org\/10.1016\/j.intimp.2025.114837.","journal-title":"Int Immunopharmacol"},{"key":"4474_CR303","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100804","volume":"6","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Li Z, Zhu Y, et al. Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Med. 2025;6:100804. https:\/\/doi.org\/10.1016\/j.medj.2025.100804.","journal-title":"Med"},{"key":"4474_CR304","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cytogfr.2026.01.006","volume":"88","author":"J Liang","year":"2026","unstructured":"Liang J, Zhu W, Pan R, et al. Spatiotemporal dynamic regulation of the CX3CL1-CX3CR1 axis: A double-edged sword in the tumor immune microenvironment and new strategies for precision therapy. Cytokine Growth Factor Rev. 2026;88:67\u201379. https:\/\/doi.org\/10.1016\/j.cytogfr.2026.01.006.","journal-title":"Cytokine Growth Factor Rev"},{"key":"4474_CR305","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102921","volume":"113","author":"A Pithakumar","year":"2026","unstructured":"Pithakumar A, Basha S, Pai AR, Mahato KK. From pathogenesis to precision medicine: targeting immune imbalance in multiple sclerosis. Ageing Res Rev. 2026;113:102921. https:\/\/doi.org\/10.1016\/j.arr.2025.102921.","journal-title":"Ageing Res Rev"},{"key":"4474_CR306","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105095","volume":"218","author":"A Thirugnanam","year":"2026","unstructured":"Thirugnanam A, Donthineni K, Mammi M, et al. Chimeric antigen receptor T-cell therapy and immune effector cell-associated neurotoxicity syndrome: a meta-analysis. Crit Rev Oncol Hematol. 2026;218:105095. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105095.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4474_CR307","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cytogfr.2025.09.004","volume":"86","author":"S Upadhyay","year":"2025","unstructured":"Upadhyay S, Upmanyu K, Gabr MT. Designing immunity with cytokines: a logic-based framework for programmable CAR therapies. Cytokine Growth Factor Rev. 2025;86:40\u201355. https:\/\/doi.org\/10.1016\/j.cytogfr.2025.09.004.","journal-title":"Cytokine Growth Factor Rev"},{"key":"4474_CR308","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2026.116530","volume":"179","author":"A Usmani","year":"2026","unstructured":"Usmani A, Siddiqui MA, Kumar D, Gowri S, Webster TJ, Faiyazuddin M. Next 5 years in autoimmunity: predictive diagnostics, immune signatures, and personalized immune therapy. Int Immunopharmacol. 2026;179:116530. https:\/\/doi.org\/10.1016\/j.intimp.2026.116530.","journal-title":"Int Immunopharmacol"},{"key":"4474_CR309","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2026.218439","volume":"647","author":"C Wang","year":"2026","unstructured":"Wang C, Sun J, Song J, Li S, Li Y. Functional nanoplatforms overcoming immune resistance in skin cancers: Targeted immunomodulation, immunogenic cell death, and metabolic remodeling. Cancer Lett. 2026;647:218439. https:\/\/doi.org\/10.1016\/j.canlet.2026.218439.","journal-title":"Cancer Lett"},{"key":"4474_CR310","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117332","volume":"242","author":"Y Yang","year":"2025","unstructured":"Yang Y, Chen R, Bao Y, et al. Recombinant AAV gene transfer: Emerging applications in immune modulation and cancer therapy. Biochem Pharmacol. 2025;242:117332. https:\/\/doi.org\/10.1016\/j.bcp.2025.117332.","journal-title":"Biochem Pharmacol"},{"key":"4474_CR311","doi-asserted-by":"publisher","first-page":"6432","DOI":"10.1182\/bloodadvances.2025017873","volume":"9","author":"KH Yoo","year":"2025","unstructured":"Yoo KH, Szymura S, Dong Z, Kandel A, Cha S-c, Kwak LW. Predictive markers for the efficacy of CAR T- cell therapy: the interplay between CAR T- cell fitness and systemic immunity. Blood Adv. 2025;9:6432\u201342. https:\/\/doi.org\/10.1182\/bloodadvances.2025017873.","journal-title":"Blood Adv"},{"key":"4474_CR312","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.1016\/j.ymthe.2025.09.049","volume":"33","author":"D Barrett","year":"2025","unstructured":"Barrett D, Cannon PM, Mingozzi F, Porteus M, Rivi\u00e8re I, Flotte TR. Overcoming barriers to commercially pre-viable gene and cell therapies for rare and ultra-rare diseases. Mol Ther. 2025;33:5316\u201326. https:\/\/doi.org\/10.1016\/j.ymthe.2025.09.049.","journal-title":"Mol Ther"},{"key":"4474_CR313","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2025.108862","volume":"271","author":"J Biber","year":"2025","unstructured":"Biber J, Gandor C, Becirovic E, Michalakis S. Retina-directed gene therapy: achievements and remaining challenges. Pharmacol Ther. 2025;271:108862. https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108862.","journal-title":"Pharmacol Ther"},{"key":"4474_CR314","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2026.102142","author":"H Brand","year":"2026","unstructured":"Brand H, Brunini B, Maron-Gutierrez T, et al. South America and Mexico\u2019s cell and gene therapy landscape: accelerating growth and persistent challenges. Cytotherapy. 2026. https:\/\/doi.org\/10.1016\/j.jcyt.2026.102142.","journal-title":"Cytotherapy"},{"key":"4474_CR315","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104562","author":"K-SN Choi","year":"2026","unstructured":"Choi K-SN, Liu W-B. Driving the future of iPS- cell- based therapy in Japan: government strategies, regulatory review and clinical development. Drug Discov Today. 2026. https:\/\/doi.org\/10.1016\/j.drudis.2025.104562.","journal-title":"Drug Discov Today"},{"key":"4474_CR316","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2026.103164","volume":"19","author":"M Fattahi","year":"2026","unstructured":"Fattahi M, Pirbadami F, Motallebirad T, Beheshti Z, Azadi D. Next-generation gene therapy for infectious disease: Advances, challenges, and future directions. J Infect Public Health. 2026;19:103164. https:\/\/doi.org\/10.1016\/j.jiph.2026.103164.","journal-title":"J Infect Public Health"},{"key":"4474_CR317","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2026.102780","author":"F Gava","year":"2026","unstructured":"Gava F, Dwivedi A, Jain H, Schultz KR, Cl\u00e9 DV, Shah NN. Overcoming challenges in implementation of CAR T- cell therapy in resource-constrained settings: Lessons from Brazil and India. Cytotherapy. 2026. https:\/\/doi.org\/10.1016\/j.jcyt.2026.102780.","journal-title":"Cytotherapy"},{"key":"4474_CR318","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104453","volume":"30","author":"LS Germain","year":"2025","unstructured":"Germain LS, Winn LM. Commercialization of cell and gene therapy in Canada: current landscape, challenges and opportunities. Drug Discov Today. 2025;30:104453. https:\/\/doi.org\/10.1016\/j.drudis.2025.104453.","journal-title":"Drug Discov Today"},{"key":"4474_CR319","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.jcyt.2024.06.002","volume":"26","author":"AO Gupta","year":"2024","unstructured":"Gupta AO, Azul M, Bhoopalan SV, et al. International society for cell & gene therapy stem cell engineering committee report on the current state of hematopoietic stem and progenitor cell\u2013based genomic therapies and the challenges faced. Cytotherapy. 2024;26:1411\u201320. https:\/\/doi.org\/10.1016\/j.jcyt.2024.06.002.","journal-title":"Cytotherapy"},{"key":"4474_CR320","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2026.102064","volume":"28","author":"SK Hashmi","year":"2026","unstructured":"Hashmi SK, Jamil MA, de la Fuente J, et al. Futuristic global cell and gene therapy regulations based on a review of today\u2019s leading frameworks. Cytotherapy. 2026;28:102064. https:\/\/doi.org\/10.1016\/j.jcyt.2026.102064.","journal-title":"Cytotherapy"},{"key":"4474_CR321","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jcyt.2025.01.017","volume":"27","author":"WYK Hwang","year":"2025","unstructured":"Hwang WYK, Muzammil EM. The current state of Cytotherapy and the field of cell and gene therapy. Cytotherapy. 2025;27:678\u201385. https:\/\/doi.org\/10.1016\/j.jcyt.2025.01.017.","journal-title":"Cytotherapy"},{"key":"4474_CR322","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102786","volume":"37","author":"B Kantor","year":"2026","unstructured":"Kantor B, Duke L, Bhide PG. CRISPR-Cas editing technologies for viral-mediated gene therapies of human diseases: Mechanisms, progress, and challenges. Mol Thera Nucl Acids. 2026;37:102786. https:\/\/doi.org\/10.1016\/j.omtn.2025.102786.","journal-title":"Mol Thera Nucl Acids"},{"key":"4474_CR323","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.141394","volume":"306","author":"MA Khorasani","year":"2025","unstructured":"Khorasani MA, Naghib SM. A review of chitosan-based multifunctional nanocomposites for drug\/gene\/protein delivery and gene therapy in cancer treatments: promises, challenges and outlooks. Int J Biol Macromol. 2025;306:141394. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.141394.","journal-title":"Int J Biol Macromol"},{"key":"4474_CR324","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2026.03.013","author":"LA Ten","year":"2026","unstructured":"Ten LA. Years of clinical genetic therapies for sickle cell disease: current and future directions. Semin Hematol. 2026. https:\/\/doi.org\/10.1053\/j.seminhematol.2026.03.013.","journal-title":"Semin Hematol"},{"key":"4474_CR325","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.reth.2024.06.005","volume":"26","author":"H Mizoguchi","year":"2024","unstructured":"Mizoguchi H, Zhang AJ, Gupta PK, et al. Regulatory systems and requirements for clinical trials of AAV-based gene therapies \u2013 Perspectives from six Asian countries or regions: Report from the 6th Asia partnership conference of regenerative medicine \u2013 April 20, 2023. Regenerative Therapy. 2024;26:334\u201345. https:\/\/doi.org\/10.1016\/j.reth.2024.06.005.","journal-title":"Regenerative Therapy"},{"key":"4474_CR326","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2026.101590","volume":"64","author":"V Moreno","year":"2026","unstructured":"Moreno V, Thistlethwaite F, Yarza R, Tak WS, Lim KHJ, Haanen JBAG. Advances in cell therapy for solid tumours: European perspective and future directions. Lancet Reg Health\u2014Europe. 2026;64:101590. https:\/\/doi.org\/10.1016\/j.lanepe.2026.101590.","journal-title":"Lancet Reg Health\u2014Europe"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04474-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04474-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04474-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T09:50:35Z","timestamp":1782294635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04474-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":326,"alternative-id":["4474"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04474-7","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"10 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declare that generative AI was not used in the creation of this manuscript. During manuscript preparation, the authors used Grammarly Premium to correct language errors. This AI-assisted tool checked spelling, grammar, punctuation, clarity, and plagiarism. Suggested corrections were reviewed and approved by the authors, ensuring human oversight throughout. This process enhanced manuscript quality by combining human expertise with tool AI efficiency.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of AI-Assisted editing"}}]}}